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CHAPTER I

INTRODUCTION

Experimental carcinogenesis in hamster buccal pouch was
first

described

by

Salley

(1954)

who

demonstrated

that

squamous cell carcinoma can be induced by repeated application
of

a

chemical

carcinogen

dimethylbenz (a) anthracene (DMBA) <1>.

such

as

7,12-

The two-stage mechanism,

defined as initiation and promotion, by Berenblum and Shubik
(1947), are independent components of carcinogenesis and was
originally

demonstrated

in

mouse

skin

where,

after

a

subcarcinogenic dose of polycylic hydrocarbons was applied,
macroscopically evident tumors could be induced to develop by
subsequent application of croton oil <6 >.
mechanism

is

composed

of

a

specific

This two-stage
and

irreversible

initiation phase in which normal cells are converted to latent
tumor cells that lie dormant until stimulated in the promoting
phase, requiring long-continued administration of large doses
of a non-carcinogenic agent such as croton oil,
1

to become

2

morphologic tumors.

The concept recently has acquired wider

validity and it has been shown to operate effectively for
hamster

pouch

epithelial

carcinogenesis

with

the

use

of

phorbol ester, 12-0-tetradecanoylphorbol-13-acetate (TPA) as
the promoting agent.
The major

recent

advance

in

the molecular

basis of

carcinogenesis has been in the field of oncogenes, which are
genes with a proven cancer association.

A small group of

genes, known as ras, is an ubiquitous eukaryotic gene family.
It was derived from the words "rat sarcoma" because these
genes were first identified as the transforming properties of
the Harvey and Kirsten strains of rat sarcoma viruses.
Ras oncogenes have been implicated in the development of
a variety of spontaneous human neoplasias (approximately 1015%)

and

in

virally

and

chemically

induced

tumors

<105 >

Identification of the activated c-rasH gene by Balmain, in the
majority of skin papillomas induced by a single application
of the carcinogen DMBA and promoted by treatment with TPA
provides for the biologic evidence that ras genes can be
activated during the early stages of tumor development <128>
Many investigations have also shown a mutational event
in the

induction of skin carcinomas in mice by DMBA and

Phorbol esters involving the specific activation of H-ras-1
oncogene by A (adenine) --> T (thymine) mutation in the second
base of codon 61

<130 >

It

is now generally agreed that

chemically induced carcinogenic process passes through the

3

steps of preneoplastic,

premalignant and malignant changes

involving the sequential evolution of genotypically initiated
cells to phenotypically altered cells.
since no such two-stage chemical carcinogenesis with a
single dose of carcinogen,

followed

by multiple doses of

promoter has been demonstrated in hamster pouch model for oral
carcinogenesis,

this investigation was undertaken to study

morphologic events and phenotypes in cells of hamster buccal
pouch epithelium initiated by the application of a single dose
of chemical carcinogen DMBA and followed by multiple doses of
promoter TPA.

Hypothetically,

the initiation of chemical

carcinogenesis that occurs in the epithelial cells, might have
the inheritable character due to alterations of the nucleotide
biochemical properties by DNA adducts formation or aberrant
alkylation of nucleotide components induced by single dose
DMBA.
the

Initiation event may be reflected during expansion of
phenotypes

by

macromolecular

TPA

that

synthesis

enhances

and

population of the initiated cells.

the

therefore

nuclear

increases

DNA
the

However, this phenotypic

expression could not be accomplished alone by promoter TPA in
the absence of initiation.
An additional
proteins,

ras

p21,

objective

is

transforming

to detect
growth

some

factor

oncogenic
alpha

and

epidermal growth factor recepter which are relevant to the
phenotypes

of

neoplastic

immunohistochemical methods.

epithelium

by

using

By the thirteenth week, we are

4

able to demonstrate de nova changes of atypia/dysplasia in the
epithelium.
Further evidence suggestive of oncogenic properties is
noted by overexpression of ras p21 protein,
growth factor alpha

(TGF- Ol) ,

tr an sf arming

and epidermal growth factor

receptor (EGF-R).
An additional semiquantitative evaluation of Langerhans
cells is also investigated.

Although Langerhans cells are

unreactive with S-100 and LN-3 antibodies in normal hamster
pouch epithelium and those treated with DMBA/TPA, they are
reactive in human oral gingival epithelium as evaluated by the
same immunohistochemical methods.

CHAPTER II

REVIEW OF THE LITERATURE

(A). Hamster Model in Carcinogenesis

Experimental carinogenesis in hamster buccal pouch
was first described by Salley (1954) who reported that
O. 5% DMBA was the most effective carcinogen, and that the

first tumor appeared after seven weeks of painting the
hamster pouch thrice-weekly <1>.

During the first two

weeks, there was an inflammatory phase with necrosis and
sloughing of the pouch epithelium.

This was followed by

healing and shrinkage of pouch mucosa.
stromal

wall

of

the

pouch

The epithelial-

passed

through

four

histologically distinct stages before the appearance of
overt

neoplasms,

degeneration

and

there

being

necrosis,

3)

1)

inflammation,

regeneration

and

2)
4)

hyperplasia <2 >.
This model had been subsequently defined by Morris
5

6

and Shklar and associates in the early sixties.

Morris

(1961) showed that the pouch epithelium of old hamsters
was more resistant to the action of DMBA than that of
young animals and that five weeks appeared to be the
optimum

age

of

hamsters

for

starting

studies

in

experimental carcinogenesis, from the standpoint of ease
of manipulation and tumor production.

A 0.5% solution

of DMBA in acetone painted on hamster pouch produced
maximum tumor yield and minimum latent period and no loss
of animals due to toxicity
A shorter

3
< >.

latent period was

required

for

tumor

development in animals when exposed to a carcinogen three
times per week than in those receiving the carcinogen
twice-weekly

3
< >.

Morris and Reiskin

(1966),

reported

that painting the pouch three times a week for 4 weeks
resulted in tumor development in all animals, but that
painting for less than 3 weeks failed to produce any
tumors

<4 >.

Salley

2 5
< • >

also discovered that heavy mineral oil

solvent reduced the latent period for tumor production
from 7 weeks to 4 1/2 weeks.

The reason for the reduced

latent period probably was due to the sustained tissue
penetration

of

carcinogen

carcinogenic action
Morris

et

al

rather

than

a

true

co-

confirmed

that

the

6
< • 7>

(1961),

also

concentration of 0.5% DMBA in heavy

mineral oil was the

7

best concentration for rapid induction of epithelial
tumors in the hamster buccal pouch <3 >.
Hamster buccal pouch is an excellent model for oral
squamous cell carcinoma,

because of

the

consistent,

predictable time patterns of tumor development, as well
as the preceding premalignant/precancerous lesions. <5 >

(B). Initiation and Promotion (Two-stage Mechanism)

Berenblum•s

early

studies

(9,

10)

in

mouse

skin

carcinogenesis suggested that induction of carcinogenesis
consisted of three phases: a) the preneoplastic phase or
precarcinogenic action, b) conversion into the wart stage
or

epicarcinogenic

action,

and

c)

the

malignant

transformation or metacarcinogenic action. Additionally,
Berenblum demonstrated that croton oil when used with a
very dilute (0.05%) solution of benzopyrene (BP), could
cause marked augmentation of carcinogenesis when applied
weekly to the skin of mice.

Subsequently, Mottram ( 1944)

showed that a single application of BP was adequate to
induce tumors in epithelium when used in croton oil <11 •
12)

Based upon Mottram' s

findings,

Berenblum (1947)

concluded that initiation process represents a sudden and
an irreversible change in a small fragment of cells of
the treated area, and giving rise to isolated "latent
tumor

cells",

apparently

indistinguishable,

8

morphologically,
cells <6>.

from

the

surrounding

non-neoplastic

The presence of these latent tumor cells is

only demonstrable by subsequent promoting action, which
converts them into morphologic tumors.
This interpretation of initiation and promotion of
chemical

carcinogenesis

accorded

well

with

that

of

Friedewald' s and Rous' s concepts <13 > of an "Initiating
Process" responsible for the conversion of certain normal
cells into latent tumor cells, and a "Promoting Process"
whereby these latent tumor cells were made to develop
into growing tumors.
1949

also

showed

Berenblum's subsequent studies in
that

the

time

interval

between

initiation and promotion was extended to almost a year
( 43

weeks)

from

the usual

one

to

two

weeks

<14 ,

15

>

However, there was no change in the mean latent period,
after

the

beginning of promotion.

supported the

concept that the

The

result

also

"latent tumor cells"

induced by single application of a carcinogen represents
an irreversible change from normal cells.
Another

quantitative

approach

to

chemical

carcinogenesis in mouse skin was analyzed by Berenblum
and

Shubik

(1947)

and

supported

the

idea

that

the

initiator determines the eventual tumor yield (tumors
induced

in

proportion

to

the

concentration

of

the

initiating agent) and that the promoter determines the
latent period <16>

If the sequence of initiation and

9

promotion is reversed, the tumor yield would not occur
because of the weak carcinogenic action of promoters <17>
Carcinogenesis
Weinstein <6 •

14

•

15

consisting of a

•

16

•

as
18

>

proposed

is probably

specific

and

by

Berenblum

and

a two-stage mechanism

irreversible

initiating

phase in which normal cells are converted to latent tumor
cells that lie dormant until stimulated in the promoting
phase to become and progress as morphologic malignant
tumors.
Berenblum <19 >

Colburn and Boutwell <20 > stated that

initiation requires only a

single application of the

chemical carcinogen to epidermis and is thus a relatively
rapid process.
stated

that

Berenblum <14 •
initiation

15

can

>,

Scribner and suss <21 >
produce

morphologic alterations in the epidermis.

no

apparent

In contrast,

promotion is a slow process requiring repeated exposure
to the promoter agent over a latent period of several
weeks (Berenblum and Shubik 194 7 <6 •
1972 <22 •

23

>,

16

>, Boutwell 1964

&

Stenback et al, 197 4 <24 >.) •

Although small doses of carcinogen can induce tumor
formation when amplified by a promoter,
dose

of

a

carcinogen

is

sufficient

to

a single high
elicit

tumor

formation without subsequent promoter treatment <25 >.

The

action of promotion on tumor formation may be reversible,
even after benign tumors have formed.

This is suggested

by the fact that discontinuation of promoter treatment

10

could result
Moreover,

in regression of many of these tumors.

increasing

the

intervals

between

promoter

application beyond the optimal time, greatly reduces or
eliminates the promoting effect on tumor formation in
mouse skin

(22, 24)

In those

treatment is modified,

instances when promoter

the initiation-promotion model

involves the sequential application of, first, a single,
essentially, non-carcinogenic dose of a carcinogen, most
commonly DMBA, followed by repetitive application, to the
same area,
ester,

of promoting agents

TPA) ,

(such as the phorbol

which produce only a

few tumors when

applied alone (promoter TPA, alone).

(C). Biological Aspect of DMBA

Chemical carcinogens are capable of interacting with
a wide variety of cellular macromolecules, which usually
involve the alkylation of nucleophilic (electron-rich)
groups on nucleic acids or proteins with electrophilic
(electron-seeking) groups of the carcinogen <26 >.
According to previous studies by Millers

(1947),

Sorof (1969 and 1974), Sarrif (1975) and Litwack (1971),
the covalent binding of various carcinogens to proteins
in target tissues has been shown already <27 •

28

•

29

•

3

o,

31

respectively).

The mechanism of chemical carcinogenesis was origin-

11
ally proposed by Pullmans (1955) who demonstrated that
in the presence of oxygen, the key epoxide formation
involved the K-region of the hydrocarbon ring structure
(32)

It is now generally accepted that conversion of

polycyclic
epoxide

aromatic hydrocarbon

is the

(PAH)

crucial pathway

to

in the

dihydrodiol
formation

of

ultimate carcinogens <33 >.
The
binding
Therefore,

dihydrodiol

epoxides

mutagenic

and

Jerina and Daly

are

the

principle

carcinogenic
(1977)

DNA

metabolites.

postulated the so-

called "bay region" theory of PAH carcinogenesis <34 >.
is that,

for

a

It

compound to be highly mutagenic and

carcinogenic, "diol epoxide" must be generated in the bay
region of the PAH molecule formed by the polycyclic
structures of the molecules.

Brookes and Lawley (1964)

also showed a correlation between DNA binding in mouse
skin and the carcinogenic potencies of PAH carcinogens
(35)

It has been shown that benzo(a)pyrene-DNA (BP-DNA)
binding in mouse skin in vivo occurs primarily through
reaction of the anti-stereoisomer of the 7-8 dihydrodiol9,

10-epoxide,

the

bay

region

dihydrodiol-epoxide

metabolite of BP, with guanine residues in DNA <~>.
chemical carcinogen,

DMBA,

belongs to the PAH.

A

DMBA

predictably initiates and promotes cancer formation in
vivo

and

in

vitro,

and

is

therefore

a

complete

12
carcinogen.
Recent studies done by Sawicki and Dipple (1983),
indicated that the binding of DMBA to mouse embryo cell
DNA involves both the syn- and anti-stereoisomer of the
3,4- dihydrodiol-1, 2- epoxide and that, in addition to
reaction with guanine,
also occurs <37 •

38

substantial binding to adenine

>.

Anita et al (1983), also identified the fact that,
by comparing the specific reaction products formed by
DMBA

and

BP

in

mouse

skin,

there

are

two

major

differences regarding the products of binding to DNA <39 >.
First, there is a more substantial modification of DNA
by the syn-stereoisomer of the bay region dihydrodiolepoxide of DMBA (40% of total DNA binding in DMBA and
only about

12%

in BP).

Second,

there

is much more

binding of hydrogen to deoxyadenosine residues when DMBA
is used (27-48% of total DNA binding in DMBA and less
than 2-3% in BP).

Any one of these differences might

account

greater

for

the

tumor

initiating

potency

exhibited by DMBA, which is approximately 20 times more
potent than is BP <39 >.
Another

example

of

carcinogen-binding

protein

discovered by Sarrif (1975) was the cytosol carcinogenbinding protein found in mouse skin and mouse liver,
after treatment with PAH <30 >.
A subsequent study demonstrated by Custer and Sorof

13

(1984), was that the amount of a 14000 MW polypetide,
which is one of the major cytosolic binding proteins in
liver

cells

for

the

hepatic

carcinogen,

2-acetyl-

aminofluorene appears to be related to the level of cell
mitosis and is high in preneoplastic foci in the livers
of carcinogen-treated rats

40

<

>.

The DNA base-adducts formation which occur in the
bay region syn- and anti-dihydrodiol epoxide of DMBA and
the resultant deoxyadenosine and deoxyguanosine adducts
in DNA and by other chemical carcinogens may distort the
helix of DNA.

This

leads to a

mutation-like event,

during DNA replication past the point of the
calation

41

<

inter-

>.

As an example, alkylated bases in DNA mispair with
wrong bases during DNA replication.

In this context,

alkyl-0-6-guanine (0-6 methylguanine) pairs with thymine
rather than cytosine, and leading to the base transition
(GC --> AT) type of mutation during the next round of DNA
replication <42 >.
guanine

residues

This species of 0-6 alkylation of DNA
has

been

shown

mutagenici ty and carcinogenicity

43

<

to

correlate

with

>.

Slago et al (1974), reported several facts about the
macromolecular synthesis of DMBA-initiated tumorigenesis
in

the

mouse

model

44

<

>.

They

found

that

a

single

initiating dose (0.05 or 0.10 umole) of DMBA depressed
DNA synthesis for 24 hours without a subsequent increase,

14
and there was no detectable epidermal hyperplasia.

Nor

was RNA or protein synthesis altered <44 >.

In contrast,

at

only

levels

of

carcinogen

which

act

not

as

an

initiator but also as a complete carcinogen when given
repetitively,

RNA,

protein

and

DNA

synthesis

were

stimulated <44 >.
According to Laerum•s and Iversen's studies, it can
be concluded that carcinogens provoke obvious changes in
some aspects of the cell kinetics of tissues <45 >
include the prolongation

of

DNA synthesis

These

time,

the

mitotic duration, and a shortening of the cell cycle of
the cells in the proliferating or growth fraction.
The

epithelial

carcinogensis
hyperplasia,

changes

induced
dysplasia

by
and

in

hamster

buccal

DMBA

are

classified

carcinoma

stages.

pouch
as
The

macroscopic and histologic changes observed preceding
neoplastic development resemble the human premalignant
conditions of oral mucosa <232 >.

The histologic changes

have been classified as hyperplasia with no evidence of
cellular

atypia,

and

dysplasia

variety of atypical features <46 >.

which

demonstrates

a

Santis et al ( 1964) ,

were able to demonstrate the existence of hyperkeratotic
and dysplastic lesions comparable to that of human oral
leukoplakia, which is a precancerous lesion <4 7>
Mork and Main (1976), used a technique to maintain
the organotypic morphology of neonatal hamster cheek
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pouch mucosa and, in 1980, reported their findings on the
effect of the single application of DMBA in vivo.

They

found that the neonatal hamster cheek pouch explants when
exposed to o. 05 ug/ml DMBA one to three hours before
being set-up in vitro, showed severe dysplastic changes
noted by 21 to 28 days, and they were similar to changes
seen in human oral premalignancy.

By 35 days, in vitro,

these changes had disappeared and the epithelium returned
its normal morphology

<4B>.

The initial irreversible

change had taken place but required a promoting agent or
stimulus in order for full neoplastic expression <~>.
The biological reaction to an initiator such as DMBA
is dose dependent.

However, as Reddy and Fialkow proved,

by using single application of different doses of DMBA
on two-stage skin carcinogenesis in BALB/c mice, not only
does

the

carcinogen cause

initiation

in mouse

skin

epidermal cells, but also the dose of carcinogen strongly
inf lucences the mode of growth of the initiated cells to
papillomas and progression of these tumors <49 >
This dose-dependency of carcinogen is based on the
hypothesis made by Scribner et al (1983), that there is
heterogeneity in papillomas as observed in promoterdependent or -independent papillomas.

This results from

carcinogen-induced variatious in the level of initiation
in target cells interpreted as "low-levels of initiation
and high-levels of initiation".

Their data strongly
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support the view that the dose of the carcinogen plays
a critical role in determining which initiated cells will
progress to malignancy during or after promotion <50 >

(D). Biological Aspect of TPA

The promoter, 12-0-tetradecanoylphorbol-13-acetate
(TPA)

is a strong inf lammatogenic and hyperplasiogenic

agent.
cells

Also, it can cause the epidermis to mimic tumor
in

a

reversible

manner.

Berenblum

(1954),

suggested that the promoting action is essentially a
process

of

delayed

maturation

of

epithelum,

thereby

allowing a sufficient number of undifferentiated daughter
cells to accumulate to form a colony of cells of critical
size

<51 >

Several investigators, such as Rover a et al <52 > and
Diamond

et

formation

(53)

al
based

on

proposed
the

a

mechanism

control

of

for

tumor

altered

cell

differentiation.

They proposed that tumor promoters

inhibit

cell

terminal

differentiation

in

vitro

by

transient blocking of cell differentation that favors
proliferation of the stem cell population.
lead to amplification of
potential

for

malignancy

cell populations where the
has

been

carcinogen but is not yet expressed.
involve

at

least

This could

two components:

initiated

by

a

Thus, promotion may
an

inhibition of
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maturation

of

basal

cells

plus

their

increased

proliferation <54 >.
TPA, when applied to squamous epithelium affects the
plasma membrane of cells and can cause a
pleiotropic responses.

cascade of

These include an elevation of

epidermal adenosine 3', 5 1 -monophosphate cyclic AMP <55 >,
stimulation

of

phospholipid

synthesis

<56 >,

increased

synthesis of prostaglandins (E2) after 10 minutes <57 •
the induction of orni thine decarboxylase <59 •

60

•

6

58

>,

TPA

1>

also affects more general inductions of gene activation;
namely, increased RNA, protein, DNA synthesis and cell
proliferation

(62, 63, 64, 65)

TPA could also alter the

morphology of mouse epidermal cells <65 >.
In addition to inflammatory effects of TPA on mouse
skin

that

infiltration,

include
there

erythema,
is

also

edema,

leukocyte

hyperplasia,

cell

dissociation and formation of dark keratinocytes <66 •

67

>

The induction and increased number of dark keratinocytes
by tumor promoters, especially TPA, has been interpreted
as a good indicator of the promoting action which was
suggested by Andres et al <6S>.
It has been demonstrated that the tumor promoting
phorbol esters produce a number of changes directly in
cell membrane and can indirectly damage chromatin by
generating "free oxygen radicals".
Cerutti

(1985)

showed

that

tumor

promoters

can
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damage DNA within chromosomes without reacting with it
directly <69 >.

They can do this by stimulating cells to

produce activated forms of oxygens including superoxide
anion radicals (02-) and hydrogen peroxides (H20 2 ) .

This

reaction is effected by the pentose phosphate pathway
that requires NADPH oxidase, which reduces oxygen to the
superoxide anion.
Tumor promoters,

in general,

induce free

oxygen

radical release in polymorphonuclear neutrophils and that
release

is

inhibited

by

anti-promoters.

Birnboim

suggested that stimulation of white blood cells with TPA,
release free radicals which can induce DNA damage in
other cells <70>.

However, this effect can be inhibited,

for example, by retinoids, which inhibit promotion of
mouse

skin

production

tumors
of

by

preventing

neutrophils

in

activated

response

to

oxygen

promoters.

Similar evidence is that some of the changes in gene
expression induced by TPA may be due to the effect of
oxygen radical generation, since induction of ornithine
decarboxylase required for cell proliferation by TPA, is
blocked

by

the

anti-oxidant

superoxide dismutase
Furthermore,

71

<

enzyme

catalase

and

>.

Cerutti showed that cells that have

been treated with TPA secrete into the incubating medium
a

destructive

clastogenic material

that

induces

chromosomal abnormalities in untreated cells.

the

It is not
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only responsible for chromosomal damage in the stimulated
cell itself but also affects the damage to neighboring
<70>.

cells

The primary action site of

the

tumor promoting

phorbol esters has been suggested to be on cell surf ace
72

membranes by many investigators

< •

73

Many of the

>

pleiotropic effects of tumor promoters, now are thought
to be due to their ability to activate a calcium and
phospholipid-dependent enzyme
75

Nishizuka and his colleagues
C (PKC).

<

74

< •

76

> first discovered by

>, known as protein kinase

PKC probably serves as a receptor for tumor

promoters
tranduction
substances

and
for
which

it
a

has

a

variety
activate

in

signal

biologically

active

crucial
of

role

cellular

function

and

proliferation.
Previous studies indicate that PKC catalyzes the in
vitro phosphorylation of a
78

<

<79 >,

>, vinculin

rich histones

(81)

40-kd protein in platelets

myelin basic protein
There

<80 >,

and lysine-

is evidence that PKC also

phosphorylates the receptors for epidermal growth factor
(EGF),

insulin and somatomedin <82 •

159

>.

Those findings

suggest that PKC is a major initial cellular binding site
and transducer of the pleiotropic effects of phorbol
ester tumor

promoters,

as well

as many

biologically

active substances.
PKC consists of a

single polypeptide chain

(MW

20
77,000) that appears to be composed of two functionally
different domains: one is a hydrophobic domain that may
bind to membranes; the other one is a hydrophilic domain
that carries the catalytically active center.
A wide variety of extracellular signals,
factors,

hormones

and

neurotransmitters,

growth
through

interaction with membrane receptors, have repeatedly been
shown to provoke the breakdown of inositol phospholipids
by phospholipase C (PLC)
activation of PKC

in their target tissues and

<54 , 85 • 86 • 87>.

At least three different messenger molecules are
known to be produced from phosphoinositides:arachidonic
acid, inositol-1,4,5-triphosphate [Ins(l,4,5)P3 ] or IP3
and

1,

2-diacylglycerol

peroxidated
respectively,

by

(DG) •

cyclooxygenase

Arachidonate

is

and

lipooxygenase,

to form the mediators:

prostaglandins,

thromboxane and leukotrienes.

IP3 functions as a second

messenger to mobolize (Ca++) i, from an intracellular site,
probably in the endoplasmic reticulum.

DG, one of the

earliest products of signal-induced inositol phospholipid
breakdown (an essential cofactor for PKC) is a messenger
that greatly increases the affinity of PKC for calcium
ion, thereby activating it.
The effect of growth factors like platelet-derived
growth factor-PDGF, and vasopressin, which activates PKC
in mouse Swiss 3T3 cells, results in increased

f~rmation
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of DG and IP3 css,

89

>•

DG operates within the plane of

the cell membrane to activate PKC, whereas IP3 oscillates
between

plasma

membrane

and

endoplasmic

reticulum

membrane resulting in oscillationally cytosolic calcium
DG is normally absent from cell

ion concentration.
membranes,

but is transiently produced from

phospholipids

in

response

receptor signals.

to

extracellular

inositol
ligand-

Some studies made by Nishizuka and

Yamanishi et al <75 ,

90

> indicate that TPA,

which has a

diacylglycerol-like structure, is able to substitute for
diacylglycerol at extremely low concentrations.

In this

manner,

TPA increases the affinity of PKC enzyme for

calcium

to the 10- 7 M range, resulting in its activation

(75, 90)

Recently, Gainer and Murray ( 1985) , also showed that
PKC

is

an

important

regulator

of

gap

junctional

permeability in cultured mouse epidermal cells (HEL-37
cells),
junction

and

that

induced

decreased
by

TPA

permeability

promoter

is

of

the

gap

mediated

via

activation of this calcium-dependent PKC enzyme, which
directly phosphorylates the gap junctional protein

<9 1>.

There is convincing evidence that the "metabolic
cooperation" that occurs between normal epithelial cells
is eliminated by TPA and it is possible that this is an
important component of the mechanism of tumor promoter
(92, 93)

Enomoto et al

(1985),

also reported that,

by
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using a fluorescent dye-transfer method to determine cell
membrane permeability, the application of tumor promoter
(TPA) to the cultured BALB/C 3T3 cells promotes the final
expression
blocking

of

phenotypes

intercellular

transmembrane

tumor

premalignant

protochannel

communications

adjacent normal cells <94 >·
that

of

among

(cell
these

cells,
to
cells

by

cell)
with

These observations suggest

promoter-mediated

inhibition

of

cell

communication might have an important role in the process
of two-stage carcinogenesis in vivo and in vitro.
Further study on the expression of tumor promoterassociated gene product was done by Peter Krieg et al
(1988).

By using the Northern Blot RNA analysis, they

were able to identify the enhanced expression of transin,
a secreted protease, which was undetectable in cells of
normal epidermis, but found only in the basal cells of
the TPA-treated epidermis.

Transin was not detected in

the nontumor-promoting hyperplastic agent, ethylphenylpropiolate (EPP)-treated epidermis <~>.

These findings

suggest that there might be a tumor promoter-associated
gene expression that could alter the cell phenotypes of
initiated colonies and offer a selective growth advantage
for tumor promotion <95 >

(E). Ras p21 Oncogene Protein
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several human tumor cell lines contain genes that
can transform NIH 3T3 cells
malignant cells.

(mouse fibroblasts)

into

Certain genes have been classified as

members of the ras oncogene family; namely, Ha-ras, Kiras and N-ras
code

for

molecular

a

<96. 99, 112, 114, 115, 116>

plasma membrane

weight

of

These ras oncogenes

bound

protein,

approximately

21,000,

having a
a

highly

related protein of 189 amino acid residues, termed p21
protein <96 >

The majority of human transforming genes

have been found to be members of the ras gene family <97 •
98

•

99

•

100

genome

>. These ras genes were initially found in the
of

certain

animal

sarcoma

viruses

<101 •

102

>

Interestingly, the ras genes have been shown to be highly
conserved during evolution,

less than 5% variation in

amino acids have been found between p21 protein of human,
rat, and even yeast origin <1o3 ,

104

>

Ras p21 is localized at the inner side of the plasma
membrane of the cells in both normal and activated status
( 178, 179)

Several functional groupings can be devised

based on the products of these genes.

For example:

protein-tyosine kinase activity->the src (avian sarcoma
virus)

family; growth factor-like activity->sis (PDGF)

family; growth factor receptor -> erb-B family; G protein
-> Ha, Ki, and N-ras family; Nuclear protein -> myc, myb,
fes, p53 and some other miscellanceous types; classified
by

Field

and

Spandidos

in

1987

(105)

Guanosine
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triphosphate-binding proteins (G-proteins) are believed
to

be the mediators

of

intracellular transducers

of

growth regulating signals and of regulation of adenylate
cyclase

and

the

members

of

a

family

of

guanine

nucleotide-binding proteins including p21 gene product
of the ras viral oncogene.

G-proteins (Got, '3 , r ) have

GTPase

hydrolysis

activity

and

the

of

GTP

favors

reassociation of Go(. and G pr subunits, thus inhibiting
their interaction with the catalytic subunit of adenylate
cyclase <106 >.
Providing
regulation

of

the

cell

gene

proliferation

expression,

the

signal

changes

or
of

the
cAMP

quantity in different cell types could reflect the fact
that the increased G protein binding activity of p21
protein also affects adenylate cyclase which controls the
level of cAMP in cells.

The binding of GTP by ras p21

protein may function as "coupling factors" in a system
relaying signals from hormonal ligands such as adrenaline
to

the

interior

of

the

cells

(signal

transducing

activity).
More recently, it has been shown directly that ras
proteins are indeed controlled by GTP and GDP: GTP-bound
forms are active and GDP bound forms are inactive, by
Trahey and McCormick <107>.
Subsequent biochemical analysis of oncogenic ras
mutants suggested that alteration in GTP hydrolysis or
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GDP/GTP

exchange

may

be

responsible

for

their

transforming activity <108>.
GTPase Activating Protein (GAP) is a 120,000 dalton
protein and has been purified recently and cloned from
bovine brain and human placenta tissue by Vogel et al and
Trahey et al

<109• 110 >

GAP can stimulate the GTPase

activity.
It was shown, by McCormick <111 >, that failure of GAP
to stimulate GTPase of several effector mutants is the
result of failure to interact with p21-GTP suggesting
that GAP is a candidate for a ras effector protein.
normal

c-ras

p21

has

intrinsic

GTPase

The

activity.

Oncogenic p21 mutants bind to GAP, but fail to undergo
downregulation

through

stimulated

GTPase

activity.

Because the mutants of H-ras have very weak GTPase (GTP
hydrolysis) activity which does not allow the conversion
of

p2 l-GTP to p2 l-GDP to which

it

no

longer binds,

delaying termination of signal transduction.
able

to

interact

with

GAP

uncontrolled signal output

continously

p21-GTP are

and

generate

011 >.

Thus, the transforming activity of an activated ras
oncogene would involve an unopposed G protein activation
event

( dysregulated and prolonged

activity of

the G

protein as a regulatory signal) lacking the normal GTPase
activity, because of the incapability of GAP to regulate
the GTPase of mutated-type p21 proteins.
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Two

hot

spots

have

been

conferred

transforming properties of the ras oncogenes.

on

the

A single

point mutation which substitutes a different amino acid
for glycine (codon 12) or for glutamine (codon 61) has
been

found

to

be

responsible

for

the

properties of H-ras genes in NIH 3T3 cells.

transformed
The point

mutation consists of the conversion of guanine (G) into
thymine

(T) ,

which

results

in

the

replacement

of

a

glycine by a valine at codon position 12 of the p21
protein encoded by the EJ cell line and T24 human bladder
carcinoma genes <117•

118

•

119

>.

The other one is the change

of the base guanine (G) into adenosine (A) resulting in
the replacement of a glycine by a glutamine at codon
position 61 of the p21 protein encoded by the chemically
N-nitroso-N-methylurea (NMU) - induced mammary carcinoma
of Buf/N rats <121 >.

The same kind of mutations leading

to activation of ras oncogenes in many human tumors have
also been reported by many investigators

<for review, 202 >.

An antibody, termed Y13-259, developed by Furth et
al <122 > has been identified that is able to neutralize all
c-ras proteins (ras p21) following microinjection into
living cells

023

>.

With this antibody, it has been shown

that ras p21 is required for the initiation of a cycle
of DNA synthesis
tested <124 >.

( S phase)

in all normal cell types

When this neutralizing anti-ras antibody

(Y13-259) was injected into NIH 3T3 cells transformed by
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growth factor receptor - like oncogenes with tyrosine
kinase activity, the transformed phenotype was abolished
and cells stopped proliferating

025

>.

The fact that anti-

ras antibody inhibited morphologic alterations in NIH 3T3
cells suggests that transformation - related morphologic
alterations

are

associated

with

the

result

of

ras

activity.
Pulciani

and

colleagues

(1985)

reported

that

morphologic transformation of NIH 3T3 mouse cells can
occur upon transfection of these cells with large amounts
(lOug) of recombinant DNA molecules carrying the normal
human H-ras-1 proto-oncogene.

Quantities of H-ras-1 RNA

and p21 expression are highly elevated in the NIH 3T3
transf ormants.

This observation indicates that elevated

expression of normal cellular proto-oncogenes can induce
oncogenic transformation in cells <126>.
Furthermore, Balmain et al (1983 and 1984) showed
serial studies of the activation of the mouse cellular
H-ras gene as compared with normal epidemis in chemically
induced skin squamous cell carcinomas and benign skin
papillomas, after sequential treatment of the Sencar mice
with initiator DMBA and promoter TPA in the dorsal skin,
then transfection of the NIH 3T3 cells with the DNA from
transplantable mouse papillomas and carcinomas ' 127•

128

>

Their results also demonstrated that H-ras gene
transcripts are elevated to a varying degree in different

28
which

papillomas

suggests

that

during

chemical

carcinogenesis in vivo, activation of the H-ras gene is
a relatively early event.

These studies indicate that

the transformation-associated activation of oncogenes or
elevation of the oncogenic products does not take place
at the transition to malignancy, but already exists in
most cells of the premalignant lesions.
Bizub et al (1986) and Quintanilla et al (1986) both
reported that the majority of DMBA-initiated papillomas
and carcinomas posses an H-ras gene sequence with a point
mutation at codon 61 <129 •

130

>.

Studies of the ras protein

p21 in tissue have been facilitated because monoclonal
antibodies reactive with ras p21 have been utilized with
formalin

fixed,

paraffin-embedded

immunohistochemical techniques

031

•

132

•

133

tissues

and

>.

Recently, using the monoclonal antibody aginst the
ras p21 protein has been evaluated in a variety of human
solid tumors by immunohistochemistry.
Thor and

their colleague

(1984)

Horan Hand and

reported that when

paraffin-embedded formalin-fixed tissue sections and the
avidin-biotin complex immunoperoxidase method were used,
the RAP monoclonal antibodies clearly defined enhanced
ras p21 expression in the majority of human colon and
mammary carcinomas, when compared with normal and benign
counterparts

<1

32

>.

Subsequently, they also reported that

ras p21 expression is correlated with depth of carcinoma
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in the bowel wall, by the same method, and is probably
a

relatively

Different

late

event

in

interpretations

colon

on

ras

carcinogenesis.

p21

expression

in

different kinds of human bladder carcinomas <134 >, thyroid
neoplasms

<1

35

>, normal and pathological liver diseases

<1 36 >,

benign colonic conditions <13n and ovarian cancers

,

have also been reported by immunohistochemical tests

(138)

from human biopsy materials.
Fujita el al (1988) also demonstrated that further
immunohistochemical
various

stages

nitrosamine

of

analysis
the

(BNN)

of

bladder

N-butyl-N

induced

tissues

at

( 4-hydroxybutyl)

carcinogenic

process

indicated that the enhanced expression of p21 appeared
early.

The reactivity with RAP-5 monoclonal antibody was

observed in diffuse hyperplastic epithelia after 5 weeks
of exposure to BBN <139>

(F). Epidermal Growth Factor (EGF)

EGF,
6000

a small 53-amino-acid polypeptide, MW about

daltons,

was

originally

isolated

from

mouse

submaxillary glands by Cohen <14 n and later from human
urine <142 >.
Extracts of the submaxillary gland from the mouse,
when injected into newborn animals, induced precocious
eyelid opening and incisor eruption <14o,

140

,

due to a

30

direct stimulation of epidermal growth and keratinization
(143, 144)

The biological responses elicited in the epidermis
by EGF include increased proliferation/differentiation
of skin tissue and accelerated keratinization in vivo,
increased rate of macromolecular synthesis (hyaluronic
RNA,

acid,

protein,

DNA),

enhanced

prostaglandin

synthesis, activation of glycolysis and stimulation of
orni thine decarboxylase activity <1 45 >.
The effect of EGF on epidermis that is probably
related to its mitogenic action is the enhancement of
carcinogenesis initiated by chemicals, for example, 3methylcholanthrene <146 •
EGF could promote

14

Rose, et al <1 47> found that

7>

tumor

formation

by shortening the

latent period and by increasing the average number of
papillomas, after treatment of mouse skin with a tumorinitiating carcinogenic chemical (3-methylcholanthrene).
Another example was demonstiated by Reynolds et al <1 46 >
Lee and Weinstein <148 > suggested that

Meanwhile,
these

chemicals,

similar

to

those

which

produce

provided

by

mitogenic
EGF,

may

activities
exert

their

biological activities by interaction with EGF receptors
(148)

It

has

been

shown

that

EGF

is

internalized

subsequent to its binding to the plasma membrane receptor
(EGF-R)

and a

major portion of the

internalized EGF
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ultimately is metabolized in lysosomes <145 >.
Protein kinase C which has tyrosine kinase activity
is believed to be the major receptor site for tumor
promoters and the cell-surface receptor for EGF.

It was

also demonstrated by Todaro et al <149> and Hollenberg et
al <150 > that some virally and chemically transformed cells
lose their ability to bind exogenous EGF to cell surface
receptor for optiomal growth.
Tumor promoters bind to PKC, resulting in membrane
association, enzyme activation, and leading to serine and
threonine phosphorylation of the EGF-R.

This event could

result in a conformational or steric change in the EGFR so that the high affinity receptor is insensitive and
can no longer bind to the EGF, and the EGF-stimulated
tyrosine kinase is only partially activated, if at all.
This

implies

an

inhibitory

stimulated tyrosine kinase.
EGF-catalyzed

are

of

the

EGF-

Moreover, it also inhibits

receptor

autophosphorylation
promoters

regulation

<151 • 152 >.

apparently

adenyl
These

cyclase
actions

brought

of

cAMP
tumor

about

by

phosphorylation, through phorbol ester-mediated protein
kinase

c,

of the EGF-R or a threonine residue at a key

site on the cytoplasmic face of the receptor near the
protein

kinase

C

domain.

PKC

phosphorylates

5'

monophosphoesterase which cleaves the phosphate 5 from
IP3 terminating the signal.
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Internalization of EGF occurs in a cell by means of
a process called receptor-mediated endocytosis, which
appears to be a common pathway for regulation of cellular
responses to a number of polypeptides, including EGF,
insulin,

transferrin,~2-macroglobulin,

immunoglobulins,

and low-density lipoprotein (LDL) <153 >-

(G). Epidermal Growth Factor-Receptor (EGF-R)

The EGF-R is a transmembrane phosphoglycoprotein of
170 kd with intrinsic tyrosine-specific protein kinase
activity

which

autophosphorylates

rather than a serine or threonine

tyrosine

<1 54 • 155 >.

residues

The receptor

binds EGF with high affinity (KD = 10· 9 to 10· 10

M) and

high specificity.
By using

125

I-labeled m EGF, a specific receptor for

EGF has been demonstrated in a wide variety of cultured
cells including corneal cells, human fibroblasts, lens
cells,

human glial cells,

human epidermal carcinoma

cells, mouse fibroblast JTJ cells, granulosa cells, human
vascular endothelial cells, human choriocarcinoma cells
and some other cell types

(Review: see 145>.

Receptors for EGF were detected by O'keefe et al
with crude membrane fractions prepared from a variety of
mammalian tissues.

These authors reported that placenta

and liver membranes have a high capacity to bind EGF

156

<

>
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After

the

amino

acid

sequence

analysis

of

six

distinct peptides from human EGF receptors of A431 cells
and

placenta

tissue

by

monoclonal

immunoaffinity

purification, Downward et al <157> were able to show that
74 out of 83 amino acid residues are identical to those
of the transforming protein coded by the V-erb-B oncogene
of avian erythroblastosis virus (AEV) <15 n.
Since the

receptors

for

EGF,

TGF- oJ.. ,

platelet

derived growth factor (PDGF), insulin and Insulin growth
factor-I
the

(IGF-I) also have associated tyrosine kinase,

structural

relationship

between

the

v-erb-B

transforming protein and the EGF receptor suggests that
other oncogenes from this

subset

( src oncogenes)

of

retroviruses could be derived in part from sequences
encoding these or other growth factor receptors, and that
tr an sf ormation

of

cells

by AEV may

result

from

the

inappropriate acquisition of a truncated EGF receptor
molecule devoid of the extracellular control domain <157>.
And, the viral transforming protein contained only the
transmembrane

and tyrosine kinase domain

of the EGF

receptor and lacked the extracellular domain responsible
for EGF binding.
As previous information in (D) Biological Aspect of
TPA, PKC can catalyze in vitro phosphorylation of the
EGF-R protein

<159>.

PKC

is

the

receptor

for

tumor

promoters <77> and when TPA is added to A431 cells, the
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EGF-R

is

phosphorylated

in

a

tryptic

phosphopeptide

identical with that phosphorylated by PKC in vitro <159•
1~>

This phosphorylation of EGF-R results in decreased

self-phosphorylation of the receptor at tyrosine residues
both in vitro and in vivo, and decreased EGF-stimulated
protein (tyrosine kinase) activity in vivo <159 >.

Thus,

PKC-ligand complex sets off changes in receptor affinity
for EGF <151 •
PKC may

152

be

indirectly

> and deactivates signal transduction.

activated directly
via

by tumor

diacylglycerol

activator of PKC,

(DG),

So,

promoter

the

or

endogenous

derived from increased phosphatidyl

inositol (Ptdins) turnover of IP3 stimulated by EGF and
other hormone-receptor interactions.
Two

types

of

identified

phosphorylation

have

different regulatory effects in EGF-R protein tyrosine
kinase activity. Self-phosphorylation enhances activity,
whereas, PKC-catalyzed phosphorylation depresses EGF-R
function (IP3 + 5 monophophoesterase -> IP2 + Pi + signal
termination,

PKC

phosphorylates

phosphomonoesterase).

EGF-R

this

activity

enzyme
of

IP3 5'-

tyrosine

phosphokinase has also become modulated by the receptor
for the other peptide growth factors including plateletderi ved growth factor <161 >, viral oncogene encoded protein
kinase <157•

162

>, TGF-o<. <163 > and PKC receptor site for tumor

promoter phorbol ester

<1

64

>.

It has been proven that the epidermal transformed
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cells and squamous cell carcinomas have high levels of
EGF-R <165 •

166

>

All growth factors are thought to exert

effects

the

in

maintaining

their

precancerous/

premalignant transformed phenotypes which express the
high level of EGF-R in transformed or altered malignant
cells, significantly <166 >.
Recently, a tumor cell line, designated A 431 cell,
derived from a human epidermal carcinoma of vulva, was
found

to

have

unique

property

of

containing

exaggerated level of EGF-R on their surfaces.

an

There are

approximately 2 x 10 6 receptors per cell, a level about
20-fold higher than the receptor levels either of normal
or transformed cell lines <167>.
Ozanne et al (1986) reported that A431 cells have
a translocation and amplification of chromosome 7 that
encodes the EGF-R <168 >.

The overproducition of EGF-R in

squamous cell carcinomas must occur during neoplastic
transformation

of

squamous

epithelial

cells.

This

increase is also found in squamous cell carcinomas biopsy
materials which have considerably greater amount of EGFR

than

found

in

normal

skin

keratinocytes,

adenocarcinomas, and small cell carcinomas of the lung,
as determined by binding with the monoclonal antibody
EGF-Rl <168 >.

Similar results were also demonstrated by

some other investigators like Cowley et al <166 >, Gusterson
et al <169 >, Hendler and Ozanne <170 >
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Taken together, these facts indicate that EGF-R gene
may function as an oncogene in epidermal malignancies and
an increased number of EGF receptors is a step in the
progression of epidermal cells into malignancy.
Several monoclonal antibodies reactive with EGF-R
have been isolated for purposes of immunohistochemistry.
Sainsbury

et

al

(1985)

reported

that

by

using

immunocytochemical techniques in certain breast cancers,
there was an inverse relationship between the EGF-R and
ER (estrogen-receptor) and a higher incidence of EGF-R
positive tumors in the metastatic group.

Additionally,

EGF-R positive tumors were of poor differentiation and
had characteristics associated with poor prognosis <171 •
172)

Another monoclonal antibody (EGF-R1) against EGFR, when used to evaluate lung cancers by immunoperoxidase
technique, also showed excellent value in distinguishing
certain kinds of positive-stained epidermoid tumors from
negative-stained normal lung tissues <170 >
Different immunoreactivities of EGF-R in different
human

tumors

such

as

cervical,

ovarian

and

vulval

carcinomas, esophageal squamous cell carcinomas, gastric
and colonic carcinomas, sarcomas have been tested with
the same technique by many investigators <174 ,

(H) . Transforming Growth Factor Alpha (TGF- 0()

175

•

176

•

177

>
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Transforming growth factors (TGFs) are polypeptides
that can induce a reversible transformation of normal
mammalian cells
cultured
acquire

cells
growth

Upon exposure to TGFs,

in culture.
will

undergo

morphologic

characteristics

transf armed cells.

typical

changes
of

and

malignant

These cells will also be able to form

anchorage-independent

colonies

transformed cells in soft agar <180 •

of

phenotypically

18

Two different

1>.

classes of TGFs have been identified: TGF-~ and TGF-~
(182)

are

These two factors bind to different receptors and
unrelated

at

the

structural

level

and

in

most

biological activities.
TGF- o< is present in multiple species, ranging in
apparent size from 5-20 kd.
amino

acids

long

and

The smallest form is 50

shares

about

30%

structural

similarity with the 53 residues long epidermal growth
factor

(EGF) •

This sequence relationship provides a

molecular explanation for the interaction of two growth
factors with the same cellular receptor-- EGF-R <183 >.
Both EGF and TGF-o<. can activate a receptor-associated
tyrosine kinase <184 >.
TGF-d... is an acidic and heat-stable transmembrane
polypeptide, MW 6000 daltons, containing 50 amino acids,
and can produce profound morphologic changes in rat,
mouse and human fibroblasts.
In 1984, Derynck et al

185
< >

reported that, by using
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mRNA derived from a human renal carcinoma cell line, they
have identified TGF-o<. c DNA.

This cDNA was found to

encode a precusor polypeptide of 160 amino acids, from
which TGF- d..

50 amino acids is derived after specific

proteolytic cleavage <185 >

In rat, this precursor has 159

amino acids <186 >
Then, in 1987, Bringman made another finding that
this TGF-C:Xprecursor contains an extracellular precursor
domain of about 100 amino acids including the N-terminal
signal

sequence

and

the

50

amino

acid

TGF-0(

a

hydrophobic transmembrane domain and a 35 residue long
cytoplasmic domain <187>.
Examination of a variety of tumor cells by Northern
hybridization

has

revealed

that

many

carcinoma

cell

lines, {especially A431 and renal carcinoma cell lines),
synthesize TGF- o<.. mRNA and the consistent expression of
the TGF-o<.gene in A431 squamous cell carcinomas and renal
carcinomas is frequently accompanied by elevated

c erb

RNA transcription and EGF-R expression {EGF-R mRNA) <188 >.
Together with the previous report made by Rosenthal et
al {1986)

that endogenous TGF-o<. expression can induce

transformation of immortalized fibroblasts through an
autocrine mechanism <1S9 >,

TGF-o( synthesis is strongly

associated with malignant transformation.
Since TGF-o(. has been shown to exert
through the EGF-R <183 •

190

•

191

>

its action

it suggests that TGF-o(.,
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synthesis could act in an autocrine fashion in these
solid tumors.
Delarco and Todaro (1978) suggested that tumor cells
may influence their own growth by producing TGFs which
usurp receptors for normal growth factors and produce an
unregulated autocrine, self-stimulating effect on tumor
cell growth <180 >
The autocrine secretion (Sporn and Todaro) <192 > of
a growth factor in cancer cells was first described in
mouse 3T3 cells transformed by either Moloney or Kirsten
murine sarcoma virus (Mo-MSV and Ki-MSV respectively) <180 •
193

>

These EGF-related peptides are now called typeot.

TGFs.
The

relationship

transformation
experiments

with

sarcoma viruses
experiments,

was

between

not

clear

TGF-Cl
until

secretion
the

temperature-sensitive
were

reported

<193 ,

194

TGF- ex was not released

•

results

mutant
195

>.

and
of

rodent

In these

into the medium

unless cells were grown at a temperature permissive for
transformation.
Another observation made by Coffey et al (1987) was
that TGF-ol_itself (and EGF) can induce TGF- ()!....expression
in keratinocytes <196 >.
been

found

in

certain

Similar autostimulation has now
other

cases

platelet-derived growth factor <197>,

like

A chain

of

interleukin-1 <195 >

and melanoma growth-stimulatory activity <199 >
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It has been shown that transformation induced by ras
oncogenes lead to induction of TGF-ot. gene expression <193,
200)

Moreover, not being limited to the MuSV-transformed

cell lines in vitro, TGF-o(. was also found in the extracts
of chemically induced bladder carcinomas

[induced in

B6D2Fl mice by N-butyl-N-(4hydroybutyl) nitrosamine) and
to a much lesser extent in the extracts of chemically
induced tracheal carcinomas

(which is a rat tracheal

transplant preexposed to DMBA) <20 1>.
Human solid tumors synthesize TGF- ol. and EGF-R in a
higher level than other types of tumors.

The expression

of TGF-o( in tumor cells strongly suggests that such cells
when in the biological status of transformation might
indicate the presence of precancerous or premalignant
condition.

Since human skin and cultured normal human

keratinocytes can produce TGF-cx, proved by Coffey <196>,
the more intense TGF-o(expression was also observed in
keratinocytes of basal cell carcinomas, squamous cell
carcinomas, and keratinocytes in plaques from psoriatic
patients than those from normal skin.

This was reported

by Gottlieb et al (1988), by using monoclonal antiTGF-

rX. antibodies (Al. 5) in frozen skin sections

<207>

(I). Langerhans Cells (LCs)

Langerhans

cells

represent

a

subpopulation

of
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Epidermal Langerhans

mammalian epidermotrophic cells.

cells are derived from bone marrow monocytic-macrophage
populations and bear surface receptors which implicate
them as immunocompetent cells <264 >.

They have receptors

for the Fe portion of IgG and the complement component
C3b c2o5 ,

206

>, and express class II MHC antigens, HLA-DR in

human(Ia-like
Langerhans

antigen

cells

in

also

(207, 208, 209)

mouse)

bear

B-cell

.

Human

alloantigens

(210)

.

Additional markers for Les in humans include antibody to
the

central

monoclonal

nervous

system

antibodies

Histochemically,

LCs

OKT6
may

demonstration

of

triphosphatase

(ATPase)

protein
(212)

also

membrane

and

be

(211)

s-100
NA

associated

(214, 215, 216)

,

and

(213)

1/34

identified

the

by

the

adenosine
gold

uptake

staining technique <225 >.
In 1973, Silberberg identified lymphocytes in direct
contact

with

Langerhans

cells

in

sites

of

allergic

contact dermatitis reactions and suggested that LCs might
play

a

role

in

the

hypersensitivity <21 n

development

of

delayed

contact

Other investigators have shown

that the LCs can migrate from epidermal sites to the
adjacent draining lymph nodes and thereby help in the
processing of the antigen <218 >.

It was suggested that LCs

are concerned with the selective uptake of different
contact

allergens,

stimulation

of

mixed

lymphocyte

reaction, and causing T cell proliferation <21 n
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The

fact

associated

that

with

antigenic

an

increased

agents
in

which

might

epithelial

including topical carcinogen DMBA application

be

tumors,
(219, 220)
I

systemic glucocorticoids <221 >, and human papilloma viruses
c222,

223

•

224

epidermal

>, have been shown to result in depletion of
Langerhans

cells

is

further

experimental

evidence to suggest that these cells may form part of the
immune surveillance system preventing the development of
malignancy in squamous epithelium.
be

involved

molecules

or

in

Therefore, LCs may

immunosurveillance
antigens

associated

against
with

specific
malignant

transformation by transporting antigens to local lymph
nodes and presenting them to specific T cells.
Schwartz

and

co-workers

(1981)

showed

that

a

decrease in density and in focal aggregates of LCs and
loss of their complex dendritic networks were found in
carcinogen (0.5% DMBA)-treated hamster pouch epithelium
for 5 weeks twice-weekly, by using ATPase staining method
(219)

With the same staining procedure,

Hassan et al

(1984) reported that there was a significant increase in
LC density after one, two or three applications of 0.5%
DMBA, ranging from 4.5 hours to 2 weeks as compared to
buccal pouches treated with mineral oil alone or left
untreated <226 >•
LCs of the oral mucosa respond to early carcinogenic
influences with an increase in number, suggestive of an
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initial cellular immune response.
decrease

of

ATPase-positive

And, the significant
LCs

in

long-term

carcinogenesis experiments in which tumors continue to
grow probably results

from

developing oral carcinomas.

immunosuppression by the
Other investigators have

shown that LCs increased in number in the cancer region
and an intimate relationship with lymphocytes in terms
of their morphologic interaction and distribution which
is suggestive of some immunological role and pathological
significance <22n.

Similar studies concerned with the

distribution of LCs and staining intensities in different
human skin tumors have also demonstrated quite different
data

<224, 22s, 229, 230>

CHAPTER III

MATERIALS AND METHODS

(A) . Animals:

Thirty-five, four to six weeks old, approximately
100 gm, non-inbred female Golden Syrian hamsters were
used.

All animals were housed in an air-conditioned room

with 12-hour light-dark cycle and given chow and water
ad libitum.

Two to three hamsters were kept in one cage.

All the cages were cleaned and sterilized at least twice
a week to maintain good hygiene and prevent spreading of
the contaminants in this area.

(B) . Facilities:

All the activities of this experiment were conducted
at HINES Veteran Administration Hospital located adjacent
to the LUMC. The animal Room Facilities-P2 containment
44

45

(ARF-P2) were located on the 4th floor of the VA outpatient-clinic, which provides for animal research and
controls the hazard substances.

Personnel involved in

this experiment and ARF-P2 area had to follow the rules
and regulations in order to prevent the exposure and
contamination from the animals and biomaterials such as
carcinogens,

and radioactive substances.

Researchers

required to wear the red surgical gown over the inner
underwears and an outer total body cover-alls which was
removed before leaving any one of the contaminated animal
experimental areas.

Researchers also had to wear two to

three pairs of disposable latex gloves, cover-cap, noseand-mouth mask (dust mist respirator) and foot-covering.
After

removing

all

protective

clothing

and

barriers

(glove, foot-covering) the individual then should wash and
change to normal dress in the locker room.

(C). Materials:

1.

RAP-5 anti-ras p21 monoclonal antibody was provided
by Dr. Jeffrey Schlom, Chief of Laboratory of Tumor
Immunology and Biology, National Cancer Institute,
National
Monoclonal

Institutes
RAP-5

was

of

Health,
developed,

Bethesda,
using

as

MD.
an

immunogen a synthetic peptide reflecting position
10-17 of the human Ha-ras T24 p21 (human T 24 bladder
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Ca cell line). This antibody has been shown to react
with both the proto-oncogene p21 and point-mutated
forms of ras p21 protein

<see reference 132 >,

and it was

determined to be the IgG28 isotype from mouse ascites
fluid.

2.

Affinity-purified
IgG(H+L)

biotinylated

horse anti-mouse

immunoglobulin was purchased from Vector

Laboratories Inc, Burlingame, CA.

3.

Affinity-purified polyclonal sheep antibody to an
TGFol synthetic peptide was purchased from Triton
Biosciences Inc, Alameda, CA.

4.

Affinity-purified

biotinylated

rabbit

anti-sheep

IgG (H+L) immunoglobulin was purchased from Vector
Laboratories Inc.

5.

Monoclonal

anti-epidermal

receptor(EGF-R).

growth

factor

This antibody is from the mouse

ascites fluid IgG 1 ,

isotype and it was purchased

from Sigma Chemical Co., St Louis, MO.

6.

Rabbit IgG antiserum to s-100 protein isolated from
cow brain was purchased from DAKO corporation, Santa
Barbara, CA.
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7.

Normal horse serum -- Vector Laboratories Inc.
Normal hamster serum -- Sigma Chemical co.
Normal rabbit serum --

Jackson Immuno Research
Laboratories

Inc.,

West

Grove, PA.

8.

Avidin-Biotin

Peroxidase

(Vectstatin-ABC

kit)

was

Complex
purchased

reagents
from

Vector

Laboratories Inc.

(D). Methods:

This experiment was begun on Jan 27, 1988, following
two-week-adaptation period of all animals to the ARF-P2
facility of HINES Hospital.

Only those hamsters that

appeared healthy and gained weight during the two weeks
were used in this study.

Application of the Chemicals

All the applications of chemicals were done by using
a camel hair brush No.5, after viewing the orifice and
fundus of the pouch to cover a 2 x 2 cm2 surface area.
A No.5 camel hair brush was dipped once in a glass bottle
that contained the solution and wiped free of excess
solution at each application.

One assistant held the
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hamster and the other everted the pouch by using two
plain tissue-forceps.

Experimental groups:
Freshly dissolved 0.5% DMBA (approximately 670 ±.36
ug DMBA per application, after calculating the difference
between the weight of dry brush and wet brush for 20
times to get the mean) in mineral oil was prepared and
applied once to all of the left pouches of 26 hamsters
and all aminals were left untreated for the rest of first
week.

Experimental control groups:
Freshly dissolved 10 ug TPA in 0.1 ml acetone
(approximately 3.73

±

1.35 ug TPA per application after

the calculating the difference between the weight of dry
brush and wet brush for 20 times to get the mean) was
prepared and applied to all the left and right pouches
of 26 hamsters three times a week from the 2nd to 13th
week. The total experimental period was thirteen weeks.
In this investigation all the left pouches were
experimental (DMBA/TPA) groups whereas, the right pouches
(TPA alone) were control groups. Time for application of
the chemicals was 6:00-9:00 A.M. every Monday, Wednesday
and Friday.

The schedule for the sacrifice of animals

was 9:00 A.M. every Wednesday.
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Normal control:
Before the beginning of this experiment, one hamster
was killed for the purpose of control tissue comparison
and

control

staining.

Two

hamsters

were

selected

randomly and sacrificed every week until the end of this
experiment.

There were another eight untreated hamsters

which

not

were

killed

until

the

20th

week

for

the

purposes of assessment of any later changes in pouches
treated with DMBA/TPA.

Sacrifice of the Animals

Before the sacrifice, two randomly selected hamsters
were injected with a lethal dose of sodium pentobarbital
(5-7

ml

per one hamster).

Then,

the

everted cheek

pouches with the exposed fundus of approximately 2 x 2
cm2 was

excised by scissors

pieces.

One piece of the pouch was put into 10% formalin

and

cut

into

two

equal

solution and the other one was put into cold normal
saline.

Tissue Storage and Processing

The pouch specimens in 10% formalin solution were
fixed six to eight hours and appropriately labelled with
code numbers before they were put into Auto-technicon for
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paraffin-embedding.
embedded tissues,

For

the

formalin-fixed

5 um serial sections

paraffin

(at

least 15

sections for each specimen) were cut and stained with
hematoxylin and eosin for histologic evaluation.
The pouch

specimens

in cold normal

saline were

brought immediately to the surgical Pathology Department
(lower level of the Russo Surgical Pavillion Building of
LUMC) and snap frozen by liquid nitrogen.

Then they were

code-labelled with numbers and stored in a deep freezer
at a

temperature

between

-75°c to -ss 0 c.

For these

tissues, serial frozen sections of 5 um in thickness (at
least 10-12 sections for each pouch specimen) were cut
in

a

cryostat

immunohistochemical

and

processed

staining.

for

Those

use

in

formalin-fixed,

paraffin-embedded tissues were also sectioned (Sum) for
immunohistochemical staining, also.

Immunohistochemical Staining Procedure

a).

Biotin

Avidin

Peroxidase

Complex,

ABC:

Immunoperoxidase on frozen sections

ABC method is based on the ablili ty of the eggwhi te glycoprotein "avidin" to bind four molecules
of the vitamin "biotin".

The avidin can attach to

both

secondary

the

biotinylated

antibody

and
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biotinylated peroxidase, producing a lattice-like
pattern

with

Finally,

the

appropriate

multiple
peroxidase

chromagen

peroxidase
are

complexes.

visualized with

(usually,

an

diaminobenzidine

tetrahydrochloride).

1.

Without thawing, the frozen tissue specimens
were placed on the cryostat chuck with OCT
compound.

The specimens were cut 3-4 micron

thick sections and placed 2-3 sections per
slide.

Then,

they were air dried for two

hours.

2.

The

slides

were

labelled

according

to

the

antibody to be used, and included the sections
to be used for positive and negative controls,
from some human solid tumors.

3.

Fixation: 15 minutes in 100% cold acetone for
all slides.
bloody,

it

If the tissue was particularly
was

washed

in

PBS.

And,

fixation was extended to 20 or 25 minutes.
this

study,

cold

acetone,

ethanol,

the
In
2.5%

formalin, and 2% formaldehyde were used as the
"fixative" in all the experimental and central
tissue sections including the normal positive
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control of different human solid tumors to
assure

useful

positive

controls.

These

included colon carcinoma, breast infitrating
ductal carcinoma, lung squamous cell carcinoma
and small cell carcinoma, laryngeal squamous
cell carcinoma,

as well

as

those

from the

experimental hamster pouch sections.

4•

Block the endogenous peroxidase of the sections
by

soaking

the

slides

into

H20 2 /methanol

solution (200 ml absolute methanol + 50 ml 3%
H202)

5.

for 15 minutes at 37°C.

Subsequently,
placedin

a

(phosphate
albumin).
minutes.

the

slides

coplin

jar

buffered

were

with

immediately
0.2%

saline/bovine

Washed two times,

PBS/BSA
serum

for each four

Tissue sections were never permitted

to be dried from this point until the end of
the procedure.

6.

In a moist chamber, the sections were covered
with a 3% solution in PBS with 0.2% BSA of
normal serum from the species in which the link
antibody was raised.
nonspecific

tissue

This was done to block
binding

of

subsequent
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reagent immunoglobulins.

15 minutes at 37°c.

Note:The dilution of BSA in PBS solution in 5
and 6 steps could be varied from 0.2% to 1%.
(In this study, normal horse serum blocked the
link antibody for RAP-5 anti-p21 and anti-EGFR,

normal

rabbit

antibody for

7.

serum

blocked

the

link

anti-TGF-~.)

The slides were tapped and wiped off excess
moisture

from

around

the

tissue

sections.

Using dispenstir, appropriate diluted primary
monoclonal

or

polyclonal

antibody

in

0.2%

PBS/BSA solution containing 1% normal serum
from the link species was added to the tissue
sections. (In this study, the dilutions were:
1:1000 for RAP-5 anti-p21, 1:50 for anti-TGFo(.

and 1: 200 for anti-EGF-R.)

Incubate 15 minutes at 37°C in a moist chamber.
However, some sections seemed to benefit from
prolonged exposure of incubation at 4°C in the
refregerator overnight to one to two days.

8.

The incubation of tissue sections in antibody
solution at this and subsequent stages was
followed by washing in three changes of PBS
solution, 5 minutes each to remove unreacted
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antibody.

9.

The biotinylated link antibodies against IgG
(whole molecule) of the species from which the
primary antibodies were prepared were diluted
in appropriate concentration (usually 1:200 in
PBS and applied to the sections for 30 minutes
in room temperature or 15 minutes at 37°C).
Note: When necessary,

diluted normal hamster

serum (1:100) was added into the link antibody
solution

to

reduce

the

amount

nonspecific background staining,

of

the

where such

unnecessary crossreactions occurred.

10.

After washing, the sections were treated with
avid in:

biotinylated horseradish

peroxidase

complex (1:200 to 1:500 in PBS) and permitted
to

react

for

30

minutes

at

25°C

room

before,

then

temperature.

11.

Slides were washed

in PBS as

rinsed with deionized water and placed in a
peroxidase

substrate

solution

for

3

minutes.

This solution consists of a

ammonium

acetate-citrate

containing

0.05%

3.3 1

buffer,

pH

to

5

o. 05%
5.5

diaminobenzidine

55
tetrahydrochloride, prepared just before use,
filtered and 0.0075% hydrogen peroxide added.

12.

After thorough washings in distilled water,
the

sections

were

counterstained

with

hematoxylin, dehydrated, cleared and mounted
in Permount.

b).

Avid in

Biotin

Peroxidase

Immunoperoxidase

on

Complex,

formalin-fixed,

ABC:

paraffin-

embedded sections

1.

Sections of formalin-fixed paraffin-embedded
tissue were cut at 3-4 um and mounted on glass
slides that were pretreated with 2% aqueous
Elmer's Glue-All.

2.

After drying in a 60°C oven for 15 minutes,
the slides were deparaff inized in two changes
of

xylene,

5

minutes

for

each

step,

then

cleared in xylene and in two changes of 100%
absolute alcohol, 5 minutes each.

3•

Blockage of the endogenous peroxidase in tissue
sections were done by soaking the sections in
3% hydrogen peroxide/methanol solution (27 ml
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methanol + 3 ml 30% H20 2 ) for 15 minutes at 37°C
in incubator.

4.

The slides were washed well with running tap
water,

followed

by

deionized

or

distilled

water.

5.

The following steps are quite the same with
the method used for frozen sections starting
from step 5.

6.

For formalin-fixed tissue sections, the slides
were treated by the same method use for frozen
sections beginning at step 5 (see above).

CHAPTER IV

RESULTS

(A). Histologic

Evaluation

of

Two-step

DMBA/TPA

Treated

Hamster Pouch Epithelium

Grossly, by the end of thirteen weeks, there was no
papilloma or tumor development in the experimental and
control groups.

Only three pouches at the 12th and 13th

weeks showed a

few areas with slightly whitish color

changes

on

the

surf aces

of

the

pouch

mucosa.

Histologically, these areas showed hyperkeratosis of the
epithelium (Figure 7).
In period I (from 1st to 5th week), DMBA/TPA and TPA
alone

groups

inflammation,

all

showed

degeneration,

some

degrees

necrotic

of

changes

acute
and

regeneration of the epithelial cells (Appendix A, iii table A, and iv-summary of period I ) .

The toxic effect

in the epithelium induced by DMBA was observed to be more
57
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prominent than that induced by TPA.

One of the features

caused by toxic effects of both chemicals was the cell
dissociation pattern. Cell dissociation occurred between
the epithelium and stroma in DMBA/TPA groups, whereas it
occurred within the epithelium

in TPA alone treated

groups.
The earliest atypia of the epithelium was observed
at the 3rd week in one of the DMBA/TPA treated groups
(Figure 2) •

It showed focal

compactness of surface

keratin, dyskeratosis, basal cell proliferation, bulbous
epithelial ridge formation and stromal reaction.

This

was interpreted as a reactive atypia due to recovery from
the toxic effect induced by DMBA.
week,

However, by the 5th

both groups showed hyperplastic changes of the

epithelia.
In period II

(from 6th to 9th week) ,

prominent

hyperchromasia of the epithelium was observed in both
experimental
groups.
showed

DMBA/TPA

Meanwhile,
stronger

and

control

TPA

alone

treated

the TPA alone treated epithelium

effects

of

hyperchromasia

of

the

epithelium than that of DMBA/TPA treated epithelium.
This may be due to the lesser inflammatory reaction and
the pleiotropic proliferative effect of promoter TPA
(Figure 3, Appendix A, iii - table Band v).
The most significant sequential changes in the pouch
epithelium were observed in period III (from 10th to 13th
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week)

of DMBA/TPA treated groups.

Focal atypia and

minimal dysplasia were observed in six out of eight (75%)
epithelia

(Figure:4,

5,

a,

6,

9 and Appendix A -

vi,

histograms and vii, summary of the results).
However, there were only three pouches at 4th, 7th,
12th weeks in TPA alone treated epithelium showing some
changes of the epithelium with focal atypia or dysplasia.
The sequential morphologic alteration in TPA alone groups
did not parallel the features of de nova atypia/dysplasia
as seen in the DMBA/TPA groups.
treated

groups

revealed

Generally,

prominent

DMBA/TPA

hyperplastic

and

atypical changes in pouch epithelium, particularly in the
third period (Appendix A iv, v, vi, and vii).
In constrast to period I, atypia at this stage was
interpreted as de nova, and was independent of initial
cytotoxic

effects by DMBA.

Two

of

the TPA treated

pouches at the 12th and 13th weeks showed intraepithelial
abscess

formation

without

direct

epithelium.

and

evidence

regenerating
of

atypical

epithelial
changes

cells
in

the

This was suggestive of the inflammatogenic

and hyperplastogenic natures of promoter TPA (Figure 10).
There were several pouch epithelia showing stromal
reaction observed at the 3rd (Figure 2) and 8th weeks of
DMBA/TPA treated groups and at the 7th,
weeks of TPA alone treated groups.

8th, and 10th

This was interpreted

as neogeneration of cellular fibrovascular connective
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tissue which replaced the oringinal superficial lamina
propr ia and pushed them downward.

These reactive changes

in the stroma might result from the cytotoxic effect
induced by both chemicals.
A single administration of carcinogen DMBA (0.5% in
mineral

oil;

approximately

670

± 36

ug

DMBA

per

application) caused morphologic changes of the epithelium
with atypia, when promoted by TPA during the following
12 weeks.

Without the carcinogen DMBA, multiple doses

(three times a week) of promoter TPA (10 ug in 0.1 ml
acetone; approximately 3.73 ± 1.35 ug per application)
did not result in morphologic changes of the epithelium
associated with atypia during the 12 weeks.

(B). Immunohistochemical Evaluation of ras p21,TGF-DC.,and EGFR in Hamster Pouch Epithelium:

Effect of the Two-step

DMBA/TPA Treatment

i).

Frozen sections of hamster pouch were used to assess
optimal immunohistochemical staining of tissues in
this investigation. Various fixatives and primary
antibody dilutions were used.
The

primary

antibodies

were

used

at

different

working dilutions ranging from undiluted to 1:2000.
The primary antibodies were used to treat control
tissue sections

in human

solid tumors

including
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squamous cell carcinomas of the lung and the larynx,
small

cell

carcinoma

of

the

lung,

infiltrating

ductal carcinomas of the breast and colon carcinoma
as well as the experimental hamster sections.
Only the control breast carcinoma and

laryngeal

squamous cell carcinoma sections fixed either in
100%

cold

acetone

or

2.5%

cold

formalin

reactive with the primary antibodies.
primary

antibody

working

dilutions

were

The optimal
observed

by

immunohistochemical stain in cells were as follows:
RAP-5 anti-ras p21, 1:1000; anti-TGF-0(, 1:50; antiEGF-R, 1:200.
None

of

the

tissue

sections

taken

from

the

experimental hamster pouches were reactive with the
primary antibodies.

The cause for

this

is not

known, however, this may have occurred during the
processing of the fresh frozen sections or during
tissue storage that resulted in the loss of any
reacting molecules in cells of the hamster pouch
epithelium.

ii). Formalin-fixed, paraffin-embedded tissue sections
of hamster pouch mucosa

a).

Monoclonal antibody RAP-5 anti-ras p21 was used
at an optimal working dilution of 1:1000 and
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resulted

in readily observable

tissue sections.

staining of

(Refer to the Appendix B -

Table I, Histograms and Figure 11 to 15 for
the results of the stains.)

Normal positive

controls for ras p21 showed positive staining
reactions in human breast carcinoma and oral
squamous cell carcinoma (Figure 12, 13). Normal
negative

control

(omission

of

the

primary

antibody) of these tumors and the experimental
tissue sections of untreated hamster pouches
did not show any positive reaction with the
ras p21 antibody.
The immunoreactivity of ras p21 was detected
as early as the 2nd week in both DMBA/TPA and
TPA alone treated groups.

The expression of

ras p21 protein was undetected in all normal
tissue sections of untreated control hamster
pouches

(Figure 11) •

(Note that one normal

hamster were sacrificed preexperimentally and
another 8 normal hamsters were sacrificed at
the experimental 20th week.)

Statistically,

there was a significant difference between the
DMBA/TPA and TPA alone treated groups.
the

statistical

Additionally,

procedures

there

was

to

(Refer

Appendix

increased

C. )

staining

intensity in cells for ras p21 observed in
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experimental

DMBA/TPA

treated

groups

from

period I to period III (Appendix B -Table I,
Histograms and Figure 14, 15) •

In contrast,

this increased staining intensity of ras p21
could not be detected in cells of hamster pouch
epithelium in TPA alone treated groups.

b).

Polyclonal anti TGF-o<antibody was used at an
optimal working dilution of 1:15 that resulted
in readily observable stain in tissue sections.
(Refer to Appendix B - Table II, Histograms and
Figure

16

staining. )

to

20

for

the

results

of

the

Positive controls for TGF- oC. showed

positive staining reactions in cells of the
oral squamous cell carcinoma and of the normal
oral squamous cell epithelium (Figure 17,18).
Normal

negative

control

(omission

of

the

primary antibody) in sections of those tissues
and that of experimental tissue sections of the
control

hamster

pouches

did

not

positive reaction with the TGF-0\

show

any

antibody.

The expression of TGF-0( protein was undetected
in

all

normal

tissue

section

of

untreated

control hamster pouches (Figure 16).
Statistically, there was significant difference
between the DMBA/TPA and TPA alone· treated
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groups

(Appendix C).

The expression of the

autocrine growth factor TGF-

0(

was stained

strongly in tissues of the DMBA/TPA treated
hamster pouches in period II and III (Appendix
B - Table II, Histograms and figure 19, 20) •
Only few scattered pouch epithelium in TPA
alone

treated

immunoreactivity

groups
with

showed
this

positive

anti

TGF-c(

antibody.

c).

Monoclonal antibody anti EGF-R was used at an
optimal dilution of 1: 500 that resulted in
readily observable stain in tissue sections.
(Refer to Appendix B - Table III, Histograms
and Figure 21 to 25 for the results of the
staining.)

The normal positive controls for

EFG-R showed positive staining reactions in the
human breast carcinoma and oral squamous cell
carcinoma

(Figure

22,23).

Normal

negative

control (omission of the primary antibody) of
the above two tumors did not show any positive
reaction with the anti EGF-R antibody.
The expression of EGF-R in normal hamster pouch
epithelium was detected at the layer of spinous
cells (Figure 21).

The expression of EGF-R

molecules was not detected at the level of
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basal and suprabasal cell
pouch epithelium.

layers

However,

in normal

in the case of

reactive and proliferating conditions of the
epithelium,

the

expression

of

EGF-R

was

detected at the level of basal and suprabasal
cell

layers

{Figure

24,25).

Statistically,

there was significant difference between the
DMBA/TPA and TPA alone treated groups (Appendix
C).
also

The stronger intensity of the staining was
observed

in

DMBA/TPA

treated

groups

(Appendix B - Table III, Histograms and Figure
24, 25).

Only few scattered pouch epithelium

in TPA alone treated groups showed positive
immunoreactivity with this anti EGF-R antibody.

(C). Immunohistochemical Evaluation of Langerhans Cells {LCs)
in Hamster Pouch Epithelium with Two-step DMBA/TPA Effect

Immumohistochemical

staining

of

formalin-fixed,

paraffin-embedded tissue sections with S-100 antibody was
unreactive with LCs of hamster pouch epithelium in this
investigation

(Figure

27).

However,

normal positive

control of several human gingival tissue sections that
stained with s-100 antibody showed positive reaction with
identifiable dendritic processes of Les

(Figure 26).

66

Schwann cells that contain s-100 protein* in nerve fiber
bundles of hamster pouch mucosa showed positive reaction
(Figure 28).

An additional monoclonal antibody, called

LN-3, specific for HLA-DR(Ia-like antigen, was also used
in this

investigation.

LN-3

is a

murine monoclonal

antibody (IgG28 ) reactive with HLA-DR (Ia-like) antigen
and

it

was

obtained

from

the

Immunobiologicals, Lisle, Illinois.

Chemical

Credential

Ia-like antigen was

present in germinal center (lymph node and tonsil) and
mantle

zone B cells,

histiocytes

and

positive control

LCs

monocytes,
in

squamous

of human

tonsil

some interdigitating
epithelium.
and

human

Normal
gingival

tissue sections were tested and showed positive reaction
with identifiable LCs (Figure 29).

Like antibody to

s-

100 protein, LN-3 did not react with any LCs in hamster
pouch epithelium (Figure 30).

(D). Statistical Analysis of the Immunoreactivity of RAP-5
anti-ras p21, anti TGF-0(. and anti EGF-R

The immunoreactivity of all three antibodies (RAP*Tissue staining with s-100 antibody: This antibody has
been tested on several formalin-fixed, paraffin-embedded human
tissues and shown to be strictly S-100 specific.
In the
brain, it stains glial and ependymal cells. Moreover, Schwann
cells of the peripheral nervous system are positive. In the
skin, melanocytes and Laugerhans cells are stained. In lymph
nodes interdigitating reticulum cells are positive. Further,
the antibody stains s-100 in benign and malignant melanocytic
tumors. (Information from the company)

r
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5,

anti

TGF-

o<..

,

anti

EGF-R)

showed

statistically

significant differences between the experimental DMBA/TPA
treated groups and control TPA alone treated groups (p
< 0.05).

Ref er the immunoreacti vi ty to Appendix B -

Table I, II, III and Histograms and refer the statistical
procedures to Appendix C for the details.
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Figure 1. Normal pouch mucosa showing slight hyperkeratosis
of

the

epithelium with

six

to

nine

layers

thickness and the underlying lamina propria.
E stain, x 100)

of
(H &
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Figure 2. The 3rd week pouch epithelium in DMBA/TPA groups
showing

reactive

atypia

of

the

epithelium with

stromal reaction. (H & E stain, x 100)
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Figure 3. The 7th week pouch epithelium in TPA alone groups
showing

very

prominent

hyperchromasia

epithelium. (H & E stain, x 200)

of

the
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Figure 4. The 10th week pouch epithelium in DMBA/TPA groups
showing the disorientation and disorganizati on of
the entire epithelial cell pattern.

x

450)

(H & E stain,
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'igure 5. The 11th week pouch epithelium in DMBA/TPA groups
showing few atypical epithelial cells with bi- and
tri-lobulated nuclei in spinous cell layer. (H & E
stain, x 450)
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Figure 6. The 12th week pouch epithelium in DMBA/TPA groups
showing

hyperplastic

epithelium

dysplasia. (H & E stain, x 200)

with

minimal
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Figure 7. The 12th week pouch epithelium in TPA alone groups
showing mild hyperchromasia and hyperkeratosis of
the epithelium.

(H & E stain, x 450)
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Figure 8. The 13th week pouch epithelium in DMBA/TPA groups
showing

prominent

hyperchromasia

and

atypical

changes of the epithelium. (H & E stain, x 450)
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Figure 9. The 13th week pouch epithelium in DMBA/TPA groups
showing prominent hyperchromasia and focal atypia
of the epithelium.

(H & E stain, x 450)

Figure 10.The 13th week pouch epithelium in TPA alone groups
showing

intraepithelial

abscess

regenerating epithelial cells.

formation

and

(H & E stain, x 200)
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..•. :..

Figure 11.The immunostaining of RAP-5 anti-ras p21 antibody
(1: 1000 dilution) in normal pouch epithelium showing
completely undetected reactivity with epithelial
cells.

(ABC method, x 200)
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Figure 12.The inununostaining of RAP-5 anti-ras p21 antibody
in positive control of human oral squamous cell
carcinoma showing positive reactivity with tumor
cells.

(ABC method, x 450)
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Figure 13.The immunostaining of RAP-5 anti-ras p21 antibody
in

positive

control

of

human

breast

carcinoma

showing positive reactivity with tumor cells.
method, x 200)

(ABC
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Figure 14.The immunostaining of RAP-5 anti-ras p21 antibody
in pouch epithelium of the 7th week DMBA/TPA groups
showing

positive

epithelial cells.

cytoplasmic

reaction

(ABC method, x 450)

with
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Figure 15.The immunostaining of RAP-5 anti-ras p21 antibody
in pouch epithelium of the 13th week DMBA/TPA groups
showing

positive

epithelial cells.

cytoplasmic

reaction

(ABC method, x 200)

with
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Figure 16. The immunostaining of anti TGF- o( antibody
dilution)

in

normal

pouch

epithelium

( 1: 15

showing

completely undetected reactivity with epithelial
cells.

(ABC method, x 200)

84

Figure

17.The

immunostaining

of

anti

TGF-0(.

antibody

in

positive control of human oral squamous epithelium
showing positive reactivity with epithelial cells.
{ABC method, x 200)
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Figure

18. The

immunostaining

positive

control

of

of

anti

human

TGF- o{
oral

antibody

squamous

in

cell

carcinoma showing positive reactivity with tumor
cells.

(ABC method, x 450)
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Figure 19.The immunostaining of anti TGF-O(antibody in pouch
epithelium of the 7th week DMBA/TPA groups showing
positive cytoplasmic reaction with epithelial cells.
(ABC method, x 450)
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Figure 20.The inununostaining of anti

TGF-~antibody

in pouch

epithelium of the 10th week DMBA/TPA groups showing
positive cytoplasmic reaction with epithelial cells.
(ABC method, x 450)
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Figure 21.The inununostaining of anti EGF-R antibody (1:500
dilution) in normal pouch epithelium showing strong
cell

membrane

reaction with
layers.
reaction.

and

moderately

epithelial

cells

weak
in

cytoplasmic
spinous

cell

Basal and suprabasal cells show negative
(ABC method, x 450)
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Figure

22.The

immunostaining

positive

control

carcinoma
cells.

showing

of

of

anti

human

positive

{ABC method, x 450)

EGF-R
oral

antibody

squamous

reaction

with

in

cell
tumor
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Figure

23.The

immunostaining

of

anti

EGF-R

antibody

in

positive control of human breast carcinoma showing
positive reactivity with tumor cells.

x

200)

(ABC method,
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•

Figure 24.The immunostaining of anti EGF-R antibody in pouch
epithelium of the 9th week DMBA/TPA groups showing
increasing positive reactivity in the cytoplasm of
basal and suprabasal cell layers.
450)

(ABC method, x
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Figure 25.The immunostaining of anti EGF-R antibody in pouch
epithelium of the 12th week DMBA/TPA groups showing
generally

increasing positive

reactivity

in the

cytoplasm of basal and suprabasal cell layers.
method, x 200)

(ABC
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Figure

26.The

immunostaining

of

s-100

antibody

(1:300

dilution) in positive control of human oral gingival
epithelium showing identifiably positive reactivity
with Langerhans cells and dendritic processes.
method, x 450)

(ABC
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Figure 27. The immunostaining of S-100 antibody in normal
hamster

pouch

epithelium

showing

completely

undetected reactivity with Langerhans cells.
method, x 450)

(ABC

95

Figure

28.The

inununostaining

bundles

of

normal

of

s-100

pouch

antibody

lamina

propria

in

nerve

showing

identifiably positive reactivity with nerve bundles
of hamster mucosa.

(ABC method, x 450)
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Figure 29.The immunostaining of LN-3 antibody (1:100 dilution)
in

positive

control

of

human

oral

gingival

epithelium showing identifiably positive reactivity
with Langerhans cells and dendritic processes.
method, x 450)

(ABC
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Figure

30.The

immunostaining of

hamster

pouch

LN-3

epithelium

antibody

in

showing

completely

undetected reactivity with Langerhans cells.
method, x 200)

normal

(ABC

CHAPTER V

DISCUSSION

In this investigation,
Appendix A

( i)

were used

a

list of certain criteria in

for

the

evalu_ation of atypical

features of the hamster cheek pouch epithelium based upon
those

established

in

previous

studies

that

thrice-weekly

application of 0.5% DMBA in mineral oil to the buccal pouch
mucosa produces histologically hyperkeratotic and dysplastic
changes of epithelium at

6 to

8

weeks,

early epidermoid

carcinoma at 8 to 10 weeks and invasive carcinomas at 10 to
12 weeks.

The microscopic and histologic changes observed

before neoplastic development resemble the human premalignant
conditions of oral mucosa <232 >.

The histological alterations

during this period have been classified as hyperplasia without
evidence of cellular atypia and dysplasia with a variety of
atypical feature.
The selection of a single application of carcinogen DMBA
followed by multiple application of promoter TPA in this
98

investigation is based upon a scheme of initation-promotion
phases of chemical carcinogenesis in mouse skin which has been
studied for years.
the

single

Typically, tumor initiation is caused by

application

of

a

subcarcinogenic

carcinogen such as DMBA or urethane.

dose

of

a

Promotion is brought

about by repeated application of a phorbol ester TPA (e.g.,
three times a week).

In this model, benign papillomas begin

their appearance at 12 to 20 weeks and by about one year
(about 43 weeks) 40% to 60% of the animals develop squamous
cell

carcinomas

(234)

Different

investigators

have

used

different amounts of DMBA for single dose application in their
studies.

For example; Salaman and Roe: total dose 0.3mg ->

0.15% DMBA in 0.2 ml acetone; Frei and Stephans: 1.5% DMBA in
mineral oil; Boutwell: 75 ug DMBA in 25 ul benzene; Van Duran:
300 ug DMBA per 100 mg acetone; Terracini et al: only higher
doses

like 100,

200,

250,

500,

1000 ug can

formation after a single application

induce tumor

C235, 236, 22, 237, 25, respectively>•

According to Scribner• s hypothesis <50 > and Reddy' s and
Fialkow' s
DMBA)

study <49 >, when the dose of DMBA is low ( o. 2 ug

there is very low frequency

of

initiated epidermal

cells, and all tumors that develop from these cells after TPA
promotion are promoter-dependent papillomas.
of

DMBA

initiation

is

responsible

not

A higher dose
only

for

the

heterogeneity of promoter dependence (because of the high or
low level of initiation), but also for the rapid development
of

the

tumors

in

response

to

TPA promotion

(

promoter-

100
independent papillomas) <49 ,

50

>.

In this investigation, initiation-promotion was induced
with a single application of the most common dose, e.g., 0.5%,
DMBA in mineral oil

(approximately 670 + 36 ug DMBA per

applications) and followed by multiple application of TPA (10
ug in 0.1 ml acetone equals approximately 3.73 + 1.35 ug per
applciation) •
As

a

result

of

this

investigation,

although

no

microscopic and histologic papillomas or tumors were found in
the pouch mucosa, there were slightly whitish color changes
observable on the surf aces of hamster cheek pouches in the
12th

and

13th

hyperkeratotic

weeks

lesions.

and

they

The

were

sequential

histologically
histomorphologic

changes with atypia that are observed in period III (10th to
13th week) of the DMBA/TPA treated groups, indeed supports the
findings of others that a single application of 0.5% DMBA can
cause variable levels of tumor initiation in epithelial cells.
The hyperchromasia, cellular atypia and other atypical
features that occur in the cells during initiation of tumors
is consistent with change in nuclear DNA.

This finding is

consistent with those that report that the distortion of the
structure of DNA over a region extending beyond the immediate
binding

site

distortion

of

stereoisomers

is

caused

nuclear
of

bay

by
DNA

region

DNA

adducts

occurs

by

formation.
syn-

and

dihydrodiol-epoxides

of

The
antiDMBA

binding to DNA guanine and adenine and 06 -methyl deoxyguanine
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(0 6-methyl

G)

mutagenic

lesions

of

DNA

will

generate

predominantly 06 -methyl G:T base pairs which gives G:C -> A:T
mutations.

several activating mutations including the ras

genes

been

have

analyzed

in

the

mouse

and

rat

tumors

containing activated oncogenes induced by carcinogens.
<238 >

Topel

suggests that the evidence of 06-methyl G mutagenesis may

be due to the persistence of

0 6 -methyl G within the

DNA

sequence and the inability to fit adducts within the ONA helix
at all positions.
dysplasia

The cytomorphologic changes of atypia and

in hamster pouch epithelium

is

consistent with

apparent sequential changes induced by DMBA/TPA in period I,
II and III.
The result of initiation is the creation of promotable
cells which set the initiated cells apart from the rest of the
tissue and allow the genotypically altered cells to change
into the dormant phenotypically altered cells.

Moreover, the

following promoting action by TPA allows the expansion of
initiated cells.

The characteristics

of

the pleiotropic

effects of the phorbol ester tumor promoters are that they can
mimic the phenotypes of both normal and transformed cells.
However, the extent of induction of phenotype of promoter TPA
is much greater in transformed cells than in normal cells.
It is clear that in cells which have been initiated by a
carcinogen the effect of promoter is permanent (irreversible)
but can not be identified until the

initiated cells have

become a major component of the cell population <53 >

Without
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the

initiation,

permanent.

most

After

of

the

the

promoter

promoter

effects

compound

is

are

not

removed

or

metabolized to an inactive form, the promoter-treated cells
revert to their original phenotypes

<53 >.

The TPA alone treatment-induced atypical changes of pouch
epithelium observed at the 4th, 7th, and 12th weeks are not
consistent with the sequential morphologic alterations of the
epithelium with
DMBA/TPA

atypia

treated

hyperchromasia,

(or

dysplasia)

groups.

increased

The
mitotic

of

period

III

in

observed

TPA-induced

figures,

basal

cell

proliferation and hyperkeratosis may be attributed to the
known pleiotropic effects of promoter TPA that result
nuclear macromolecular synthesis.

in

These changes in TPA alone

treated epithelium do not parallel de novo atypical features
of the initiated cells induced by DMBA/TPA because of the
inconsistency of histologic changes from period I to period
III in this present investigation.
The microabscess formation and reactive hyperplasia in
epithelial cells observed at the 12th and 13th weeks of TPA
alone treated groups

(Appendix A,

ii,

and Figure 10)

are

suggestive of the strong inflammatogenic and hyperplasiogenic
effects of promoter TPA.
A

strong

association

between

enhanced

inflammatory

response and reactive hyperplasia in skin to TPA and enhanced
sensitivity to tumor promoter by TPA has been demonstrated by
Lewis and Adams (173) in Sencar and C57BL/6 mice.

The stromal
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reaction observed in both groups of this investigation might
indicate the cytotoxic effect in the stroma induced by two
Similar

chemicals.

stromal

reactions

in

hamster

pouch

epithelial cultures treated with a small dose of DMBA was
reported by Mock et al in 1983 <233 >.
This investigation demonstrates the initial histologic
alterations induced by a single dose of DMBA and promoted by
multiple doses of TPA in hamster buccal pouch epithelium.
Early reactive atypia observed at the 3rd week of DMBA/TPA
treated epithelium (Figure 2)

is interpreted, following the

recovery from acute toxic effect of carcinogen.

Excluding

reactive features, de novo expression of atypia in DMBA/TPA
treated epithelium during the third period suggests expansion
of the initiated cells by the action of promoter TPA.
induced

morphologic

changes

of

enhancement

DNA/nucleoprotein replication (hyperchromasia)
proliferation,
carcinogenesis,

particularly
is

an

in

important

the

third

acquired

carcinogen treated epithelial phenotype.

DMBAof

and cellular
period

of

property

of

This phenomenon of

an increase in cell replication during these early steps may
suggest "resistance" to normal mitoinhibitory effect of cell
proliferation.

Moreover, this feature confers initiation of

the altered epithelial cells as they are readily responding
to promoters action, in contrast, to the control counterpart.
The expression of ras protein (p21) in DMBA/TPA treated
epithelium, but not untreated epithelium is consistent with
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initiation and gene activation.

It has

activation

to

of

ras

gene

appears

been shown that

participate

in

the

development of several forms of human cancer and in virally
and chemically induced tumor <120 >.
Because of the requirement of protein product of the ras
proto-oncogene for initiation of the S-phase (DNA synthesis)
in NIH 3T3 cells <124 > and the stimulation of G-protein binding
activity and phosphorylation of ras oncogene protein by EGF
<239 >,

the ras p21 protein can fulfill the function of a G-

protein in growth factor induced signal transduction, which
has an integral role in the control of cell di vision and
proliferation. •
The sequential increased stainability of ras p21 during
period III of DMBA/TPA treated pouch epithelium indicates its
increased production and accumulation
cells.

of

this protein

in

However, the earliest expression of ras p21 molecule

can be detected at the second week of both experimental
DMBA/TPA and control TPA alone treated groups.

Previous

studies have shown that elevated expression of the Ha-ras
proto-oncogene is an early event in developing mouse skin
papillomas produced by the standard two-stage carcinogenesis
(241, 242)

In Felling' s study <242 >, elevated levels of Ha-ras RNA

can be detected at the 7th week in early papillomas of Sencar
mice and the presence of a point mutation at codon 61 can be
detected in 9-week-old papillomas.
In addition, elevated levels of C-rasH gene transcripts
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in

benign

papillomas

containing

DNA

with

detectable

tr an sf orming activity have also been reported by Balm in

<1ZS>.

It appears that ras genes have a very wide range of biological
effects depending on the sequential addition of qualitative
and quantitative changes that occur during the initiation and
promotion phases of chemical carcinogenesis.
While this experimental design does not provide for
assessment of qualitative difference of ras p21, the increased
expression of ras p21 in period III (DMBA/TPA treated groups)
supports not only the occurrance of an effective initiation
event

but

also

the

associated

cellular

atypia

that

is

consistent with cell transformation.
The scattered expression of ras p21 protein in TPA alone
treated epithelium may be associated only with the morphologic
changes

of

focal

epithelial hyperplasia.

The

increased

expression of ras gene has been reported in regenerating rat
liver cells cz45 >.

Thus appreciation of the overexpression of

ras p21 in neoplastic process also occurs in active stages of
cell proliferation during normal cell regeneration.
Finally, in the investigation, it is evident that the
morphologic, immunohistochemical and statistical (P < 0.05)
analyses

together,

provides

for

confirmation

that

the

sequential overexpression of this molecule (ras p21 protein)
is strongly associated with the phenotypes of the sequential
morphologic alterations of pouch epithelium with atypia (or
dysplasia)

in DMBA/TPA treated pouch

epithelium.

While
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overexpression of p21 is essential for the phenotypes of the
initiated cells, it is not specific.
In general, the proto-oncogene forms are thought to be
involved in the normal growth control of cells, while the
mutated forms appear to be responsible, in part, for the loss
of normal growth control of neoplastic cells proliferation
<51 >

It is possible, however, that overexpression of mutated

ras p21 occurs after a single application of DMBA and multiple
application of promoter TPA.

This might cause the observed

early preneoplastic changes of the pouch epithelium found in
this investigation.
Comparison of the immunostaining in pouch epithelial
cells of both groups with polycolonal antiTGF-0(.

antibody

supports the sequential overexpression of TGF-OC..molecule as
it occurred only in DMBA/TPA treated groups, and not in TPA
alone treated groups.

Moreover, this significant difference

between the experimental DMBA/TPA and TPA alone treated groups
is supported by the statistical analysis {P < 0.05).
Importantly, the increased immunostaining of
the 6th week (in period II and III)
relationship

between

atypia

(or

TGF-~after

indicated the strong
dysplasia)

and

overexpressed TGF-O(in DMBA/TPA treated pouch epithelium.

the
The

direct evidence from previous studies have shown that TGF-«
is frequently enhanced or induced by neoplastic transformation
and its synthesis is very prevalent and abundant in tumor
cells and

cells

transformed

by

oncogenes,

chemicals

and
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retroviruses.

This accompanied elevated TGF-O(expression in

DMBA/TPA treated epithelium with atypia also suggests the
implication of an autocrine or paracrine secretion.

It is

believed

could

that

transforming

growth

factor

alpha

contribute to normal and neoplastic growth through autocrine
and paracrine mechanisms

<192 >.

The

binding

of

TGF-0(

to

receptor (EGF-R) on the surface of the target cells initiates
a sequence of cellular responses including the activity of the
receptor's

intrinsic tyrosine kinase,

culminating in cell

proliferation.
The overexpression of ras p21 and

TGF-~protein

in this

investigation indicates a cooperative role for these products
in DMBA/TPA treated epithelium.
mammary epithelial
proto-oncogene

have

It has

been

cells transformed by an
increased

secrete their own TGF-ot <200 >.

capacity

to

shown that

activated ras
synthesize

and

Sporn and Roberts <192 > stated

that GTP-binding activity of transforming Ha-ras p21 enhanced
by

EGF,

presumably

by

TGF- D<..

further

supports

that

cooperative function of secretion of TGF-o(by ras-transformed
cells has a role in amplifying the signalling pathway.
In this panel of immunostaining, the expression of TGFol... in normal oral oral

squamous epithelium

positive control) is also demonstrated.

(as a

normal

TGF-o<. has been found

to be synthesized by normal skin keratinocytes, and activated
macrophages.

The TGF-O(mRNA is also found to be transiently

synthesized in placenta, developing kidney, the nasopharyngeal
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pouch and the otic vesicle, indicative of its possible role
in

growth

and

differentiation

under

embryologic

and

physiologic conditions.
Lack of the sequential responsiveness of anti TGF-Ol
antibody in TPA alone treated epithelium is interpreted as
being consistent with the morphologic alterations without
atypia.

Like the ras p21 protein, the increased expression

of TGF- Cl(. is thought to be an early event in preneoplastic
changes of the epithelium.

It is also an essential,

but

nonspecific cause for the observed phenotypes of the initiated
cells.
It is known that normal keratinocytes of the epidermis
express controlled amounts of the EGF-R on their surfaces.
In this panel of immunostaining, the expression of EGF-R in
normal pouch epithelium is detected in spinous cells.

Because

the EGF-R usually is not detected at the basal and suprabasal
cell layers in normal pouch epithelium, this may be used as
the criteria for any changes of the quantity of expression in
the pouch epithelium of DMBA/TPA and TPA alone treated groups.
From the table

III

(Appendix B),

it is evident that the

increased staining of cells for EGF-R in DMBA/TPA treated
groups

indicates

an

increased

expression

in

these

cells

greater than those observed in the TPA alone treated groups,
and

that

the

difference

between

that

two

groups

is

significant.
The increased expression of EGF-R molecule in DMBA/TPA
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treated

epithelium

is

based

upon

the

positive

staining

reactions localized to the basal and suprabasal cell layers.
This

demonstrates

a

strong

relationship

between

the

consistently overexpressed EGF-R and the morphologic changes
in DMBA/TPA treated epithelium.

In this investigation, the

increased expression of EGF-R

is clearly associated with

initiation and promotion events.
Although the increased expression of EGF-R protein has
been reported repeatedly in epidermal carcinoma cell lines
such as A431 cell line and other human tumor biopsy materials
(172-178)
I

this investigation is the first observation on the

sequential

overexpression

of

this

receptor

chemically-induced preneoplastic changes

of

molecule

in

hamster pouch

epithelium.
The EGF-R, MW 170,000, is a transmembrane glycoprotein
formed

in many cell types.

Its function

is to bind the

mitogen EGF and to the transduce the signal across the cell
membrane to cytoplasm.

The EGF-R binding event induces a

variety of receptor-mediated downregulation of growth factors,
hormones,

neurotransmitters,

including

ion

transport,

morphologic changes and ultimate mitogenesis.
Protein kinase C (PKC) has been found to be the receptor
for

tumor

promoters

and

it

has

intracellular signal transduction.

an

important

role

in

A substrate for PKC is

EGF-R itself, and activation of the former molecule appears
to occur in response to growth factors through the generation
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of diacylglycerol (DG) by the activation of different isotypes
of phospholipase C (PLC) on the phosphoinositides of the cell
membrane.

The modulation of EGF-R by a pathway including DG

and PKC provides a mechanism whereby EGF and TGF-0( can act
sequentially in stimulating growth and cell proliferation.
The dual overexpression of TGF-OCand EGF-R in these DMBAinitiated, TPA-promoted sequential morphologic alterations in
pouch epithelium further supports the role for these two
molecules in the phenotypes of initiated cells.

In addition

to the fact that EGF-R might serve as a good indicator for
clinical tumor behaviors and prognosis in the cases of certain
breast and colon cancers, the increased expression of EGF-R
in

this

investigation

occurs

in

the

early

stages

of

preneoplastic changes of the epithelium.
Statistically, the expression of these three molecules
(ras p21, TGF-o<., EGF-R) shows a significant difference (p <
0.05) between the experimental DMBA/TPA treated and TPA alone
treated

epithelium.

Moreover,

the

phenotype-related

morphologic alterations, particularly in the period III of
DMBA/TPA treated groups, are strongly associated with the ras
p21, TGF-o(.and EGF-R activities.

This suggests that the gene

activities are cooperative in the sequential overexpression
of these molecules in experimental groups and differ from the
lack of this sequential responsiveness to antibodies in the
control TPA alone treated groups.

The increase in expression

of these molecules supports not only the idea of promotion in
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which tumor promoter induces the sequential overexpression of
phenotypes that are necessary for the initiated cells but also
the existence of initiated cells that have been induced by
carcinogen DMBA.
As demonstrated (Appendix B), the im.munoreactivity of
these three molecules are presumably due to the action of
tumor

promoter,

which

are,

in

turn,

sequential expression of phenotypes.
dependent,

since

these

reactions

essential

to

the

This event is timeare

not

significantly

detected immediately following the DMBA application.
The induction-maintenance of such phenotypes of DMBAinduced initiated cells

is prerequisite for preneoplastic

changes and it may offer selective growth advantage as well
as

phenotypic

morphologic

changes.

changes

In

with

addition,

atypia

in

the

the

sequential

DMBA/TPA

treated

epithelium and the overexpression of these oncogenic molecules
lend

support

to

the

thesis

that

carcinogenesis

is

a

multigenetic-and-multistage mechanism.
Immunologically,

it

is

possible

to

induce

variable

alterations in the quantity and the quality of Langerhans
cells in epithelium that range from acute toxic effect of DMBA
to changes in the epithelium,

although Schwartz et al and

Hassan

different

et

al

demonstrated

qualitative changes

in Langerhans cells

quantitative

and

of hamster pouch

epithelium after various applications of 0.5% DMBA in mineral
oil

<219,226>
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In this investigation, Langerhans cells of hamster pouch
epithelium
antibodies.

are

neither

reactive

with

s-100

nor

LN-3

It is possible for Langerhans cells in hamsters

to carry unique species-specific molecules that are quite
different from that of human except for Schwann cells, as they
contain s-100 protein and HLA-DR (Ia-like) antigen.

CHAPTER VI

CONCLUSION

This investigation demonstrates the initial morphologic
alterations induced by single dose DMBA (0.5% in mineral oil)
promoted with sufficient intensity by TPA (10 ug in 0.1 ml
acetone) in hamster cheek pouch epithelium.

According to the

theory of "level of initiation" proposed by Scribner, it is
believed that single application of 0.5% DMBA must have caused
variable levels of initiation in pouch epithelium and it might
affect the phenotypes of initiated cells.

This early event

of the carcinogenic process in pouch epithelium is timedependent (12-week-promotion) and subsequent to the recovery
due to tissue injury caused by carcinogen DMBA.

Meanwhile,

this investigatory design of initiation and promotion does not
induce any gross tumor development by 13 weeks.
The early reactive atypia could be induced following the
recovery from the acute toxic effect of DMBA.

Excluding

reactive features, de novo expression of atypia in DMBA/TPA
treated epithelia during the 3rd period (10th to 13th week)
113

114
suggests expansion of the initiated cells by the action of
promoter TPA.

Such atypia is not expressed in TPA alone

treated epithelia without the

initiation.

Promoter

TPA-

induced morphologic changes in TPA alone treated epithelia do
not parallel the atypical features.
The immunoreactivity of RAP-5 anti-ras p21, anti

TGF-~

and anti EGF-R antibodies supports, in part, the phenotypes
of initiated cells as they are responding to the promoter TPA
and undergoing the preneoplastic changes.
there

is

a

significant

difference

(p

statistically,
<

0.05)

between

immunoreactivity of these antibodies found in the experimental
DMBA/TPA and the control TPA alone treated epithelium.

The

immunohistochemical responsiveness of ras p21, TGF-tiland EGFR to antibodies does coincide with the morphologic changes
with atypia in the DMBA/TPA treated epithelium, but not in the
TPA alone treated epithelium.
morphologic

alterations

associated with

the

of

result

so,

the
of

the phenotype-related,

epithelium
ras

p2 l,

are

TGF-o<.

strongly
and

EGF-R

immunoreactivities due to the sequential overexpression of
these three molecules.

As

compared

to

the normal

pouch

epithelium, the overexpression of oncogenic molecules is an
early event prior to the clinical benign tumor development.
The relationship between the phenotypes of initiated cells
and the overexpression of these three oncogenic molecules is
interpreted as "essential" but "nonspecific".
the activation of ras p21,

TGF-~

In other words,

and EGF-R molecules is a
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basic integral event and prerequisite during the prenoplastic
changes

of

the

epithelium,

and

it

coincides

with

the

phenotypes of the initiated cells under the action of promoter
TPA.
Langerhans cells in hamster pouch epithelium may carry
unique molecules quite different from those in humans species
except

for

Schwann cells,

due to

the

immunohistochemical

unresponsiveness to S-100 and LN-3 antibodies.
The sequential morphologic changes with atypia in single
dose DMBA-initiated and multiple doses TPA-promoted pouch
epithelium

and

increased

expression

of

ras

p21

oncogene

product, transforming growth factor alpha and epidermal growth
factor receptor suggest the emergence and diversity of the
initiated

cells

following

the

sequential

evolution

of

carcinogenic process that is a multistage-and-multi genetic
mechanism.
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APPENDIX A

(i)

criteria for Histologic Evaluation of Hamster Pouch Epithelium
(1). Epithelial hyperplasia: proliferation of epithelium
including acanthosis,
basal cell proliferation or
elongation of epithelial ridges.
(2). Focal atypia: changes in individual cells without
disorientation or disorganization of their arrangement
and pattern.
a).
b).
c).
d).
e).
f).
g) •
h).
i).
j).
k).

1).
m).

compactness of surface keratin
dyskeratosis
keratin pearl formation in the spinous cell layer
hyperchromasia
large prominent nucleoli
cellularpleomorphism: anisocytosis, poikilocytosis
alteration of N/C ratio
loss of the cellular polarity
increase in the number of mitoses
suprabasal mitosis
atypical or bizzare mitosis
bulbous epithelial ridges
lack of the cohesiveness of the epithelial cells

(3). Dysplasia:
atypia
disorganization or
arrangement.

as
the
above
criteria
with
disorientation of the cellular

minimal - less than 4 items
moderate - at least 5 items
severe
- at least 8 items
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APPENDIX A

(ii)

Brief Histologic Report and Staging of Each Pouch Epithelium

*Brief Histologic Findings from 1st week to 13th week:
1). 1-27-N (Normal Hamster Pouch)

(Figure 1)

Normal Hamster Pouch is composed of a keratinized
stratified squamous epithelium and its underlying lamina
propria of fibrous connective tissue.
A).
B).
C).

D).
E).

stratum corneum (parakeratosis or orthokeratosis):
usually one to two layers of thickness
stratum granulosum (granular cell layer): with
keratohyaline granules (one layer of thickness)
stratum spinosum
(spinous cell
layer):
from
suprabasal polyhederal cells to upper spinous cells
with intercellular spaces between cells (three to
five layers of thickness)
stratum basale (basal layer): low cuboidal to tall
columnar cells (one layer of thickness)
lamina propria:
a). superficial layer - dense fibrocollagenous
connective tissue containing moderate amount
of fibroblasts, small blood vessels and nerve
bundles.
There is no papilla in superficial
lamina propria, epithelial rete-ridges and
salivary glandular structures.
b). deep layer (submucosal layer) - It is a loose
fibrous conncetive tissue with blood vessels
and nerves of larger sizes and muscle bundles.

2). 2-3-1W,D-A-L't
separation of the epithelium from the stroma
epithelial necrosis
intensive acute inflammation
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scattered dyskeratotic cells
colloid bodies formation
atypical giant nucleated cells in the spinous cell
layer (due to toxic effect)
mild acanthosis
minimal hyperchromasia of basal and suprabasal cells
with prominent nucleoli
roughness of the basement membrane
3). 2-3-1W,D-B-L't
severe inflammation
focal
mononuclear
cell
infiltration
in the
epithelium
hyperkeratosis
colloid bodies formation
dyskeratotic cells (dyskeratosis)
few giant nucleated cells with prominent nucleoli
in the suprabasal & spinous cell layer
very mild cell dissociation in the epithelium
mild basal cell proliferation and hyperchromasia
mild disorientation of the cell pattern, focally
epithelial hyperplasia
intraepithelial microabscess formation
4). P-2W,DT-A-L't
focal hyperkeratosis
focal acanthosis
moderate inflammation in the stroma (lymphocytes,
monocytes, neutrophils, few mast cells)
focal basal cell proliferation
granulation tissue formation
few dyskeratotic cells
5). P-2W, T-A-R't
focal acanthosis
focal basal cell proliferation
focal compactness of surface keratin
mild hyperchromasia of the basal cells
mild mononuclear cell infiltration
6). P-2W,DT-B-L't
focal acanthosis
mononuclear cell infiltration with
formation
lymphocytes, monocytes predominant
7). P-2W,T-B-R't

microabscess
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focal compactness of surface keratin (or compact
hyperkeratosis)
few inflammatory cells (lymphocytes)
epithelial dissociation from the stroma, partially
focal acanthosis
mild hyperchromasia of the basal cells
few dyskeratotic cells
8). P-3W,DT-A-L't
focal compactness of surface keratin
increased mitotic figures
mild hyperchromasia of basal cell layer
basal cell proliferation
few suprabasal mitoses
few scattered dyskeratotic cells
lymphocytes & mononuclear cell infiltration
9). P-3W,T-A-R't
compact keratin formation
focal acanthosis
basal
cell
proliferation
and
focal
mild
hyperchromasia
few inflammatory cells
subcorneal microabscess formation (neutrophils)
10). P-3W,DT-B-L't
focal compact hyperkeratosis
acanthosis
severe inflammation with lymphocytes, monocytes,
mast cells
neogeneration of cellular f ibrovascular tissue
beneath the epithelium
disorientation of the basal/suprabasal cells
basal cell proliferation with minimal dysplasia and
bulbous ridge formation (no invasion)
severe mononuclear cell infiltration
colloid bodies formation
dyskeratosis
increased mitotic figures
slight separation between epithelium & stroma
minimal dysplasia of the epithelium
reactive atypia of the epithelium (due to the toxic
effect of DMBA)
11). P-3W,T-B-R't
few cells show granular and clumped chromatin in the
nucleus
suprabasal mitosis
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few inflammatary cells (neutrophils)
focal acanthosis with basal cell proliferation
12). P-4W,DT-A-L't
intraepithelial microabscess formation
moderate inflammation in the stroma
suprabasal mitosis
epithelium dissociation
dyskeratotic cells
few giant nucleated cells with prominent nucleoli
in the spinous cell layer
focal acanthosis with basal cell proliferation
few cells with pleomorphic, hyperchromatic nuclei
in the basal cell layer
13). P-4W,T-A-R't
subcorneal microabscess formation
focal acanthosis with basal cell proliferation and
mild hyperchromasia
increased mitotic figures
suprabasal mitosis
slight disorientation of cell pattern in the
epithelium
mononuclear cell infiltration
moderate inflammation in the stroma
focal atypia of the epithelium
14). P-4W,DT-B-L 1 t
focal acanthosis and hyperkeratosis
moderate inflammation
microabscess formation in the subcorneal cell layer
mild mononuclear cell infiltration
15). P-4W,DT-B-R 1 t
focal compactness of surf ace keratin
focal acanthosis and basal cell proliferation
subcorneal microabscess formation
few colloid bodies formation
dyskeratotic cells
few inflammation cells
mild mononuclear cell infiltration
16). P-5W,DT-A-L't
few inflammatory cells
mild separation between the epithelium and stroma
mild compact hyperkeratosis
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17). P-SW,T-A-R't
focal acanthosis
focal microabscess formation in the epithelium
few basal cells show the granular or clumped
chromatin
few inflammatory cells
18). P-SW,DT-B-L't
subcorneal microabscess formation
focal compactness of surf ace keratin
dyskeratotic cells
mild inflammation
separation between the epithelium and stroma
few suprabasal mitoses
19). P-5W,T-B-R 1 t
mild elongation of epithelial ridges
mild acanthosis
mild hyperkeratosis
mild inflammation (lymphocytes, monocytes)
granulation tissue formation
20). P-6W,DT-A-L't
subcorneal
and
intraepithelial
microabscess
formation
suprabasal mitosis
colloid bodies formation
epithelium necrosis
cell dissociation in basal cell layer, focally
moderate inflammation
mononuclear cell infiltration
focal area showing the giant nucleated cells with
prominent nucleoli in the spinous cell layer
focal atypia of the epithelium
21). P-6W,DT-A-R't
hyperkeratosis
minimal inflammation
focal acanthosis
22). P-6W,DT-B-L't
some inflammatory cells
no significant changes in the epithelium
23). P-6W,T-B-R 1 t
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focal acanthosis and basal cell proliferation
some inflammatory cells
no singificant changes in the epithelium
24). P-7W,DT-A-L't
mild inflammation in the stroma
focal acanthosis and mild hyperkeratosis
mild hyperchromasia in basal cell layer
focal compact hyperkeratosis
focal basal cell proliferation
25). P-7W,T-A-R't
focal hyperkeratosis
moderate hyperplasia of the epithelium
moderate hyperchromasia of the basal cells with some
squamoid differentiation
mild cell dissociation in basal cell layer
neogeneration of cellular f ibrovascular tissue with
roughness of the basement membrane
moderate inflammation
few colloid bodies formation
some dyskeratotic cells
granulation tissue formation in the stroma
intraepithelial microabscess formation
epithelium necrosis
mild dissociation of the epithelium from the stroma
elongation of epithelial ridges with dyplasia
disorientation of the suprabasal and basal cell
layers
no invasion of the dysplastic epithelium
minimal dysplasia of the epithelium
26). P-7W,DT-B-L 1 t
focal compactness of surf ace keratin
some inflammatory cells ( neutrophils, mast cells}
27). P-7W,T-B-R't
mild acanthosis of epithelium
few inflammatory cells
28). P-8W,DT-A-L 1 t
hyperkeratosis with compactness of surface keratin
mononuclear cells infiltration
mild neogeneration of cellular f ibrovascular tissue
lymphocytes, monocytes, and neutrophils
focal
basal
cell
proliferation
with
mild
hyperchromasia
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focal epithelial hyperplasia
29). P-SW,T-A-R't

focal compactness of surface keratin
focal acanthosis of the epithelium
few inflammatory cells
30). P-SW,DT-B-L't

mild inflammation
focal compactness of surf ace keratin
no significant changes in the epithelium
31). P-SW,T-B-R't

mild compactness of surf ace keratin
few inflammatory cells
mild acanthosis
slight hyperchromasia in basal cell layer
32). P-9W,DT-A-L't

very few inflammatory cells
focal acanthosis
mild hyperchromasia in the basal cell layer
a lot of perivascular mast cells infiltration
mild basal cell proliferation
33). P-9W,T-A-R 1 t

few inflammatory cells
edematous change in the stroma
focal acanthosis with mild basal cell proliferation
34). P-9W,DT-B-L 1 t

mild inflammation (lymphocytes, neutrophils, and
mast cells)
focal basal cell proliferation
focal acanthosis
scattered dyskeratotic cells with pyknotic nuclei
focal hyperkeratosis
35). P-9W,T-B-R't

mild neogeneration of cellular f ibrovascular tissue
intensive mononuclear cell infiltration
mild hyperkeratosis
focal acanthosis and mild basal cell proliferation
focal hyperchromasia of basal cells
lymphocytes, monocytes, mast cells in the stroma
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36). P-lOW,DT-A-L't
subcorneal microabscess fromation
dyskeratotic cells
suprabasal mitosis
cell dissociation in the basal cell and suprabasal
cell layer
mononuclear cell infiltration
focal acanthosis
few giant nucleated cells in upper spinous cell
layer
focal basal cell proliferation
colloid bodies formation
granulation tissue formation in the stroma
moderate inflammation
mild disorientation of the suprabasal and spinous
cell layers
focal atypia of the epithelium
37). P-lOW,T-A-R't
small
amount
of
neogeneration
of
cellular
f ibrovascular tissue
cytoid bodies formation and few dyskeratotic cells
mild inflammation
focal acanthosis
38). P-lOW,DT-B-L't
scattered dyskeratotic cells
few inflammatory cells
focal acanthosis
39). P-lOW,T-B-R't
mild inflammation
focal acanthosis
no significant changes in the epithelium
40). P-llW,DT-A-L't
focal hyperkeratosis
focal acanthosis
moderate hyperchromasia of basal cell layer
few cells with bi/tri-lobulated nuclei in the
suprabasal and spinous cell layer
cell dissociation in the basal cell layer
mild inflammation (lymphocytes, monocytes, mast
cells)
mild mononuclear cell infiltration
mild squamoid differentiation in basal cell layer
perivascular mast cells infiltration
few cells with hyperchromatic and pleomorphic nuclei
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in the basal cell layer
focal atypia of the epithelium
41). P-llW,T-A-R't
slight inflammation & edema in the stroma
no significant changes in the epithelium
42). P-llW,T-B-L't
mild cell dissociation in the basal cell layer
moderate inflammation (lymphocytes, neotrophils,
mast cells)
focal acanthosis
basal cell proliferation with hyperchromasia
mononuclear cell infiltration
intraepithelial/subcorneal
layer
microabscess
formation
few degenerating epithelial cells with pyknotic
nuclei
43). P-llW,T-B-R't
focal acanthosis
mild inflammation
large amount of mast cells in the strma
focal bascal cell proliferation
mild mononuclear cell infiltration
moderate inflammation
44). P-12W,DT-A-L't
focal hyperkeratosis of the epithelium
moderate inf lamination
focal basal cell proliferation
intraepithelial microabscess formation
focal acanthosis
generalized hyperchromasia of basal cells with some
pleomorphic nuclei and mild squamoid differentiation
intensive mononuclear cell infiltration
some atypical cells with clear cytoplasm and
pleomorphic nuclei in basal cell layer
cell dissociation between the basal cell layer and
stroma
focal disorientation/disorganization of the cell
pattern
minimal dysplasia of the epithelium
45). P-12W,T-A-R't
focal acanthosis
few inflammatory cells
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scattered dyskeratotic cells
mild hyperchromasia in basal cell layer
46). P-12W,DT-B-L't

focal acanthosis
mild
basal
cell
proliferation
with
focal
hyperchromasia
mild inflammation
epithelial necrosis
some squamoid differentiation in the basal cell
layer
mild pleomorphism of the basal cell layer
focal disorientation of cell pattern
minimal dyplasia of the epithelium
47). P-12W,T-B-R 1 t
focal hyperkeratosis (compact type)
cell dissociation in the basal cell layer
epithelial necrosis
basal cell hyperchromasia
moderate inflammation
focal acanthosis
elongation
of
epithelial
ridges
with
hyperchromatic epithelial cells
focal basal cell proliferation
mild disorientation of the cell pattern
minimal dysplasia of the epithelium

some

48). P-13W,DT-A-L't
focal hyperkeratosis of the epithelium
few colloid bodies formation
few dyskeratotic cells
atypical giant nucleated cells in the upper spinous
cell layer
generalized hyperchromasia of the basal cells with
mild pleomorphism
focal basal cell proliferation with squamoid
differentiation
focal cell dissociation in the basal cell layer
moderate inflammation
loss of cell pattern and arrangement, focally
mononuclear cell infiltration, intensively
minimal dysplasia of the epithelium
49). P-13W,T-A-R't
few inflammatory cells
focal acanthosis
no significant changes in the epithelium
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50). P-13W,DT-B-L't

focal acanthosis
basal
cell
proliferation
with
moderate
hyperchromasia
moderate inflammation (lymphocytes, mast cells,
neutrophils)
some squamoid differentiation in the basal cell
layer
few dyskeratotic cells
granulation tissue formation
minimal dysplasia of the epithelium
51). P-13W-,T-B-R 1 t

focal acanthosis
focal basal cell proliferation
severe intraepithelial abscess formation (lymphocytes, neutrophils)
severe inflammation in the stroma
focal regenerating epithelial cells between the
areas of abscess formation
52).
53).
54).
55).
56).
57).
58).
59).

P-20W,C-A
P-20W,C-B
P-20W,C-C
P-20W,C-D
P-20W,C-E
P-20W,C-F
P-20W,C-G
P-20W,C-H

*All the control groups showed the
normal histology of hamster pouch
epithelium.
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(ii)

*Brief Staging of Each Pouch Epithelium
Acute inf ammation ==> AI
Pustule/Abscess ==> P/A
Epithelial necrosis/degeneration ==> En/d
Chronic inflammation ==> CI
Epithelial hyperplasia ==> EH
*Focal atypia ==> FA
minimal ==> Dmi
*Dysplasia moderate ==> Dmo
severe ==> Dse
*Stromal reaction
(Neogeneration of f ibrovascular tissue) ==> SR
* * * * *
Al P/A Enid Cl EH FA Dmi Dmo Dse SR

1). 1·27-N

nonnal pouch

2). 2·3·1W,D·A·L 1 t

x

3). 2·3-1W,D·B·L't

x

x
x

x

x x

4). P-2W,DT-A-L't

x x

5). P·2W,T-A-R 1 t

x

x

6). P-2W,DT·B·L 1 t

x

7). P·2W,T-B·R 1 t

x

8). P-3W,DT·A·L't

x x

9). P·3W,T-A·R't

x x

10). P·3W,DT·B·L't

x

x x

x x

11). P·3W,T-B·R 1 t
12). P·4W,DT·A·L't

x

x

x x

13). P-4W,T-A-R 1 t

x

x

x x x

x

x x

14). P·4W,DT-B·L't

x

x
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*

*

* *

Al P/A En/d CI EH FA Dmi Dmo Dse SR
15). P·4W,T-8·R't

x

16). P·5W,DT·A·L 1 t

x x
x

17). P-5W,T·A·R•t

x

x

18). P-5W,DT·8-L 1 t

x

x

x x

19). P·5W,T·8·R't
20). P·6W,DT-A·L 1 t

x

x x x x

21). P-6W,T·A-R't

x x

22). P-6W,DT·8-L 1 t

x

23). P·6W,T·8·R't

x

24). P-711,DT-A·L't

x

25). P-711,T·A-R't

x x

26). P·711,DT·8-L 1 t

x

27). P-711,T-8-R't

x x

28). P-8W,DT-A-L't

x

x

x

x

30). P-8W,DT·8-L 1 t

x

31). P·8W,T-8·R't

x x
x

33). P-9W,T·A-R't

x

x

x x
x x

34). P-9W,DT-8·L 1 t

x x

35). P·9W,T-8·R 1 t

x

x

36). P·10W,DT-A-L't

x

x

37). P·10W,T-A·R't

x x

38). P-10W,DT-8·L't

x

x

40). P·11W,DT·A·L 1 t

x

41). P·11W,T·A·R't

x

43). P·11W,T·8·R 1 t
44). P·12W,DT·A·L 1 t
45). P·12W,T·A·R't

x
x

x

x x

39). P-10W,T·8·R't

x

42). P·11W,DT-8·L't

x

x

x

29). P·8W,T·A·R 1 t

32). P·9W,DT-A·L 1 t

x

x

x

x x

x x

x

x

x x

x x

x
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*

*

*

* *

Al P/A En/d Cl EH FA Dmi DlllO Dse SR
46). P·12W,DT·B·l 1 t

x

x

x x

x

x

x x x

48). P·13W,DT·A·l 1 t

x x

49). P·13W,T·A·R 1 t

x x

50). P·13W,DT·B·l't

x x

x

x

x

x

x

51). P·13W,T·B·R 1 t

x

x x

52). P·20W,C·A

control group ········> normal pouch

53). P·20W,C·B

control group ······-·> nor111&l pouch

54). P·20W,C·C

control group ·······-> normal pouch

55). P·20W,C·D

control group ········> normal pouch

56). P·20W,C·E

control group ---·····> normal pouch

57). P·20W,C·F

control group ········> normal pouch
control group

59). P·20W,C·H

-------->

normal pouch

control group ····--··> normal pouch

* summary:
A. Number of epithelial dysplasia/atypia
Left side (DMBA + TPA)
Right side (TPA)

==>
==>

==>

8 pouches
3 pouches

B. The earliest changes of dysplasia/atypia
DMBA/TPA treated ==> 3rd week
(others: 6th,10th,llth,12th,13th)
TPA treated only ==> 4th week
(others: 7th,12th)

c.

Number of stromal reaction
Left side (DMBA + TPA)
Right side (TPA)

==>
==>

==>

5 pouches

2 pouches
3 pouches

D. The earliest changes of stromal reaction
DMBA + TPA treated ==> 3rd week
TPA treated only
==> 7th week
(the others: 8th, 9th, 10th)

11 pouches
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(iii)
Comparison of the DMBA & TPA Effect
During the Carcinogenesis Process
TABLE A: 1st - 5th week (Period I)

I nfl anmat ion
- acute & chronic
- epithelial dissociation
- epithelial necrosis
- intraepithelial abscess formation
- mononuclear cell exocytosis
- perivascular mast cell infiltration

+++
+
++
++

++
+

++
+/·
+
+
+

+/-

Epithelial Changes
c~ct keratinization
hyperkeratosis
acanthosis
colloid bodies
basal cell hyperplasia/proliferation
bulbous epithelial ridge formation
acantholysis of the epithelial cells

Atypia/Dysplasia
- large prominent nucleoli
- hyperchromasia
- pleanorphism
- increased mitosis
• si..,rabasal mitosis
- atypical mitosis
- loss of cellular orientation/arrangement
• lack of epithelial cells cohesiveness
- dyskeratosis
• squamoid appearance in basal cell layer
Stromal Reaction
(neogeneration of f ibrovascular connective tissue)
Note:

strong reaction
moderate reaction
+
weak reaction
+/· occasionally weak reaction
negative reaction
+++
++

+
+/-

+

++
+
+
+

++
+/+

+/+
+/-

+/+/·

+/·

+/+/+/·

+/+/·
+/·

+/+

+/-

+/-
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APPENDIX A
(iii)
Comparison of the DMBA & TPA Effect
During the Carcinogenesis Process
TABLE B: 6th • 9th week (Period JI)

I n I nfl arrmati on

•
•
·
·
•

acute &chronic
epithelial dissociation
epithelial necrosis
intraepithelial abscess formation
lllOl'lOnUClear cell exocytosis
perivascular mast cell infiltration

Epithelial Changes
• COR-.:>SCt keratinization
- hyperkeratosis
• acanthosis
• colloid bodies
- basal cell hyperplasia/proliferation
- bulbous epithelial ridge formation
- acantholysis of the epithelial cell
Atypia/Dysplasia
· large prominent nucleoli
· hyperchromasia
- pleomorphism
- increased mitosis
• suprabasal mitosis
- atypical mitosis
· loss of cellular orientation/arrangement
• lack of epithelial cells cohesiveness
· dyskeratosis
• squamoid appearance in basal cell layer
Stromal Reaction
(neogeneration of fibrovascular cornective tissue>
Note:

+++
++

+
+/·

strong reaction
moderate reaction
weak reaction
occasionally weak reaction
negative reaction

++

++

+
+
++

+

+

++

+
+
+/·
++

++

++

+

+
+

+
+

+/·

+
+/-

+

+/·

+/·

+/·

+/·
++
+/·

+
+/·

+/+/·

+/-

+/+/-

+/-

+/·

+/+/·

+
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APPENDIX A
(iii)
Comparison of the DMBA & TPA Effect
During the Carcinogenesis Process
TABLE C: 10th - 13th week (Period Ill)

lnflanmation
- acute & chronic
- epithelial dissociation
- epithelial necrosis
• intraepithelial abscess formation
• lllOl'\Ol"IUC l ear cell exocytos is
• perivascular mast cell infiltration
Epithelial Changes
- conpact keratinization
- hyperkeratosis
- acanthosis
- colloid bodies
- basal cell hyperplasia/proliferation
- bulbous epithel fal ridge formation
• acantholysis of the epithelial cells
Atypia/Qysplasia
- Large prominent rucleoli
- hyperchromasia
• pleomorphism
- increased mitosis
- suprabasal mitosis
- atypical mitosis
- loss of cellular orientation/arrangement
- lack of epithelial cells cohesiveness
- dyskeratosis
- squamofd appearance in basal cell Layer
Stromal Reaction
(neogeneration of fibrovascular connective tissue)
Note:

+++
++
+

+/·

strong reaction
lllOderate reaction
weak reaction
occasionally weak reaction
negative reaction

++
++
+
+

++
+

+++

+
+
+

++

++

+/++
+

++

+

++
+/-

+/+
+
+

+

+/-

+
++
+

+/+++

+

+/-

+
++

+
++

+/+/-

++

+/-
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APPENDIX A

(iv)

Summary of Period I:

Similarity:
1. DMBA and TPA can cause some degrees of inflammation,
degeneration, necrosis and regeneration of epithelial
cells.
2. By 5th week, DMBA and TPA all caused some hyperplastic
effect on epithelium.
3. Few scattered atypical cells can be found in DMBA/TPA and
TPA alone groups at the 3rd & 4th weeks, respectively.
Difference:
1. DMBA can cause more severe inflammmatory (toxic) effect
in host response.
(more abscess formation)
2. DMBA -- Dissociation occured between the epithelium and
stroma.
TPA -- Subcorneal cell layer separation.
3. More bulbous type of epithelial proliferation in DMBA/TPA
groups.
4. DMBA/TPA groups caused a very early reactive atypia due
to the recovery form acute toxic effect of DMBA in the
epithelium at the 3rd week.
5. At the 4th week, TPA alone treated pouch showed the
earliest focal atypia of the epithelium. (due to
increased suprabasal mitosis, slight disorientation of
cellular pattern and basal cell proliferation)
6. The earliest stromal reaction occurred in DMBA/TPA groups
(the 3rd week).
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APPENDIX A

(iv)

Summary of Period II:

Similarity:
1. Both DMBA/TPA and TPA groups had about the same degree
of inflammation and epithelial changes.
2. TPA caused the stromal reaction, too.
Difference:
1. TPA alone groups did show a little stronger effect to
cause the hyperchromatism, epithelial hyperplasia and
squamoid appearance of the epithelium, which might be
associated with the pleiotropic influence of TPA in vivo.
2. TPA caused a minimal dysplasia of epithelium at 7th week.
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APPENDIX A

(iv)

Summary of Period III:

Similarity:
1. Both DMBA/TPA and TPA alone groups had about the same
degree of inflammatory reaction.
Difference:
1. DMBA/TPA groups had more pronounced hyperplastic
proliferation and more
atypical
changes
in the
epithelium.
(de novo changes of dysplasia/atypia)
2. Although TPA caused a very prominent hyperchromasia in
the
epithelium.
(increased
the
number
of
dark
keratinocytes), the morphologic changes in TPA alone
groups were not consistent with the atypia/dysplasia.
3. TPA caused more stromal reaction.
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APPENDIX A

(v)

Comparison of I, II & Ill period CDMBA/TPA gr0l4)6)
lnfl81T1118tion

Epithelial Hyperplasia

Atypia/Dysplasia

Period

+++

+

+/-

Period II

++

+

+/-

Period III

++

++

++

===================================================================================================
Comparison of I, II & I II period (TPA gr0l4)6)
I nfl 81T1118t ion

Epithelial Hyperplasia

Atypia/Dysplasia

Period

+

+

+/-

Period II

+

++

+/-

Period Ill

++

++

+/-
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APPENDIX A
(vi)
Histogram of the Results of Histologic Evaluation
Time

(week>
13th
12th
11th
10th
9th
8th
7th
6th
5th

Inf:
EH:
FA:
Dmi:
Omo:
Dse:

4th
3rd
2nd

lnfl8111118tion
Epithelial Hyperplasia
Focal Atypia
Minimal Dysplasia
Moderate Dysplasia
Severe Dysplasia

c:::J B h81118ter pouch

1111

1st

A hamster pouch

'---1--1---1--1--1--1----lnf

* DMBA

EH

FA

Dmi

Omo

+ TPA treated pouches (left pouch)

Dse

Epithelial
Changes
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APPENDIX A
(vi)

Histogram of the Results of Histologic Evaluation
Time

(week)

13th
12th
11th
10th
9th
8th
7th

11111111111111111

6th
5th
4th

111111111

3rd
2nd

1st

Inf:
EH:
FA:
Dmi:
Dmo:
Dse:

Inflanmation
Epithelial Hyperplasia
Focal Atypia
Minimal Dysplasia
Moderate Dysplasia
Severe Dysplasia

c:::::::J

B hamster pouch

1111

A hamster pouch

:--:---:---:--:--1----EH
FA
Dmi Dmo Dse Epithelial

Inf

Changes

* TPA treated pouches (right pouch)
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APPENDIX A

(vii)

Summary of the Results of Histologic Evaluation

1) •

The earliest change in epithelial cells was found in
DMBA/TPA groups at the 3rd week.
This was interpreted
as reactive atypia, and was following recovery from acute
toxic effect of DMBA.

2) .

Epithelial hyperplasia occurred in both groups within
first 5 weeks (period I) .

3).

TPA-treated pouches revealed prominent hyperchromasia of
the epithelium in both experimental and control groups.

4) •

Generally,
DMBA/TPA
groups
revealed
prominent
hyperplastic and atypical changes in pouch epithelium,
particularly in the third period. Atypia at this stage
was interpreted de novo, in contrast to period I, and
independent of cytotoxic reaction by DMBA. Such atypia
was not expressed in TPA alone treated epithelia.

*

Note:

Grossly, by the end of the 13th week, there was
neither papilloma or tumor growth in this
experiment.

APPENDIX B
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Table I: lllllaM'lOStaining of RAP-5 anti-ras p21

wk

1st 2nd 3rd 4th 5th 6th 7th 8th 9th

Left

CA) -

DM8A
+TPA

(8) -

Right CA)
TPA

(8)

Note: +++
++
+
+/-

+

+

+/-

+/-

+

+

+/-

+/-

+

+

+/-

strong reaction
moderate reaction
weak reaction
occasionally weak reaction
negative reaction

10th 11th 12th 13th

++

+

++

++

++

++

+

+/-

+

+

+

+

+/-

+/-

+

+/-

+/-

+

+

+

+

+/-

++
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Table II: lllllll'lOStaining of anti TGF-o<.

wk
Left

1st 2nd 3rd 4th 5th 6th 7th 8th 9th 10th 11th 12th 13th
(A) •

+/·

+/·

++

+

+/-

+++

+

+

+/-

++

+

++

+/-

+/·

++

+/-

+/-

+/-

+

+/-

++

+

DMBA

+TPA (8) -

Right (A)
TPA

(8)

+/-

Note: +++ strong reaction
++ moderate reaction
+
weak reaction
+/· occasionally weak reaction
negative reaction

+/·

++
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Table III: JllllM.»'lOStaining of anti EGF-R

wk

1st 2nd 3rd 4th 5th 6th 7th 8th 9th 10th 11th 12th 13th

Left (A)

+

DMBA
+TPA

+

(8)

+

+

+

+

+

+

+

++

+

++

+

+

+/-

+

+

++

+

+/-

+

+

++

+

++

+

Right (A)
TPA

(8)

++
+/-

+/-

Note: +++ strong reaction
++ lllOderate reaction
+
weak reaction
+/- occasionally weak reaction
negative reaction

+
+

+
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Time
(week)

13th

111111111111111111111

12th

11111111

11th

11111111

10th

11111111

9th

11111111

8th
7th

11111111

6th
5th
4th

*

RAP·S anti·ras p21

3rd
2nd

c:::::::::::J B h11111Ster pouch

1111

1st

1--1--1
(·)

(+/-)

(+)

(++)

A hamster pouch

1--1--1---(+++)

Score of the
Staining

*

DMBA

+

TPA treated pouches Cleft pouch)
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Time

(week>

111111111111111111111

13th
12th
11th
10th

111111111

9th
8th
7th
6th
5th
4th
3rd
2nd

c::::J B hamster pouch

1111

1st

A hamster pouch

...____, _ _ ,___ - - - 1 - - 1 - - 1 - - - (·)

*

(+/·)

(+)

(++)

(+++)

DMBA + TPA treated pouches (left pouch)

Score of the
Staining
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Time

(week)

13th
12th
11th

11111111

10th
9th
8th
7th
6th
5th
4th

* anti EGF-R
3rd
2nd

1st

c::::J

B hamster pouch

1111

A hamster pouch

1--1---1--1--1--1----(-)

*

DMBA

(+/-)

+

(+)

(++)

(+++)

TPA treated pouches Cleft pouch)

Score of the
Staining
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Time
(week)

13th
12th
11th
10th
9th
8th
7th
6th
5th
4th

* RAP-5 anti-ras p21
3rd
2nd

c:::::l B

1111

1st

(-)

*TPA

hamster pouch

A hamster pouch

:--:---:--1--1--1-----

(+/-)

(+)

(++)

(+++)

treated pouches (right pouch)

Score of the
Staining
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Ti!lle
(week)

13th
12th
11th
10th
9th
8th
7th

111111111111111

6th
5th
4th

*

anti TGF-o<

3rd

111111
2nd

c:::::J B hamster pouch

1111

1st

A hamster pouch

'---1--1---:--1--1--1----(·)

*

(+/·)

(+)

(++)

(+++)

TPA treated pouches (right pouch)

Score of the
Staining
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Time
(week)
13th
12th
11th
10th
9th
8th
7th

111111111111111111111

6th
5th
4th

* anti EGF-R
3rd
2nd

c:::J B hamster pouch

1111

1st

A

hamster pouch

1--1---1--1--1--1----(-)

*

(+/·)

(+)

(++)

(+++)

TPA treated pouches (right pouch)

Score of the
Staining

APPENDIX C

174

APPENDIX C

Statistical Analysis of the Im:munoreactivity of RAP-5anti-ras
p21 antiTGF- 0( and antiEGF-R

"Two Sample T test" is used in this statistical analysis to
conclude whether there is statistically significant difference
between the experimental DMBA/TPA treated groups and TPA alone
treated groups, or not. This method can also be considered
as an extension of the "analysis of variance" (one way block)
which actually works with the "squares of the deviation"
instead of "square roots of the variances".
In order to analyze the grading system (-, +/-, +, ++, +++)
that we used for the im:munostaining of these three antibodies,
we give a serial of numbers (2,4,6,8,10 respectively) for the
scores.
It does not have to be this set of numbers.
Any
other serial of numbers also work perfectly with this
statistical analysis.
i).

RAP-5anti-ras p21:
After the replacement of the grading system with numbers
and putting A scores and B scores together in each
groups, we have the following scores of left and right
pouches for RAP-5anti-ras p21. (Original grading is in
Appendix B table I.)
1st 2nd 3rd 4th 5th 6th 7th 8th 9th 10th 11th 12th 13th
L
R

4

8 10

6 10

8 14 10 14

14

14

14

10

6

4

6 10

10

10

6

4

8

8

6 12

The Null Hypothesis (Ho) is that:
If UL

= UR,

there is no significant difference between the left
and right pouches. Otherwise, we have to reject the
Ho. And, there is significant difference between
the left and right pouches.
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XL = sum of the scores of left pouches = 136

=

NL

=

total samples of left pouches

XL

=

mean of the scores of left pouches

-

13

=

136/13

=

90

x L2 -- 42 + 82 + 10 2 + 6 2 + 102 + 8 2 + 14 2 +
2
10 2 + 14 2 + 14 2 + 14 2 + 14 + 102

=

1560

sum of the scores of right pouches

NR

=
=

total samples of right pouches

XR

=

mean of the scores of right pouches = 90/12

~

=

XR2 = 62 + 82 + 42 + 82 + 62 + 102 + 62 +
12 2 + 10 2 + 10 2 + 6 2 + 4 2

=
"two

s~le

748

T test 11

[(N1 - 1>s, 2 + <N2 - 1)S22J
(N1

+

N2 - 2)

N2 - 1

=

=

<X1 - -X1> 2
N1

=

=

+

+

<X2 - -X2> 2

N2 - 2

12

176
t

=

X1 - Xz

X1 - Xz

=

S/F

s

ITT
I

2

[1560

s2P =

-

(136) 2/13] + [748 - (90) 2/12]

13 + 12 - 2

=

9.1404682

s = JsP2

=J 9.1404682 =

3.0233207

136/13 - 90/12

t =

J 1/ 13

3. 0233207
df

= NL + NR - 2

= 13

=

+ 1/ 12

2.4469522

+ 12 - 2 = 23
= degree of freedom

Check the P values for different T and dt in the t Table.
dt

p -->

0.05
2.07

23
p

*

(at 0.05) < t

0.02
2.50

0.01
2.81

(=2.4469522) < p (at 0.02)

We set p (OC. value) at 0.05 (5%) •
So, we reject the Ho.
And, we can conclude that there is statistically
significant difference between left pouches (DMBA/TPA)
and right pouches (TPA alone) for RAP-5anti-ras p21.

ii) • antiTGF-o(:
1st 2nd 3rd 4th 5th 6th 7th 8th 9th 10th 11th 12th 13th
L
R

4 4 4 4 10 10 12 14 10
6 8 4 4 8 12

4 8

18

10

10

10

6

4

4

4
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XL = 120

~ = 72

13

NR = 12

NL =

=

XL

120/13

~

XL 2 = 1328
(1328 -

=

72/12

=

6

~2= 504

(120) 2/13] + (504 -

(72) 2/12]

13 + 12 - 2

=

12.70903

s = Jsp2
t

= 3.5649726
120/13 - 6

=

3. 5649726
df

=

J l/ 13

13 + 12 - 2

= 2.2638212

+ 1/12

= 23

Check the t Table.

p -->

0.05
2.07

23

P (at 0.05) < t

*

0.02
2.50

0.01
2.81

(=2.2638212) < P (at 0.02)

we set P ( c< value) at o. 05 (5%) •
So, we reject the Ho.
And, we can conclude that there is statistically
significant difference between left pouches (DMBA/TPA)
and right pouches (TPA alone) for antiTGF-OC.

iii).antiEGF-R:
1st 2nd 3rd 4th 5th 6th 7th 8th 9th 10th 11th 12th 13th
L 14

8

8 10 12 12 14 12 12

R

4

4

6

6

4 10

4 12

12

14

14

12

4

8

10

8

178

=

154
XL
13
NL =

Xa

= 80

NR

12

= 154/13
2
xL = 1876

Xa = 80/12

XL

s2P

[1876

=

X., 2= 624
2

(154) /13] + [624 -

(80) 2 /12]

13 + 12 - 2

=
s

-

=

6.1895247

=P

=

6.1895247 = 2.4878755
120/13 - 6

t

=

2. 4878755

j

1/ 13 + 1/12

= 5.2005648

Check the t Table.

p -->

23

P (at 0.05) << t

*

0.05
2.27

0.02
2.50

0.01
2.81

(=5.2005648)

we set P Co<.value> at 0.05 (5%).
So, we reject the Ho.
And, we can conclude that there is statistically
significant difference between left pouches (DMBA/TPA)
and right pouches (TPA alone) for antiEGF-R.
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